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Abstract 
Cholera continues to be an important cause of morbidity and mortality in large parts of the 
developing world and is a significant negative factor for economic development. Vibrio 
cholerae bacteria of the O1 or O139 serogroup can cause disease due to their ability to 
colonize the intestine and produce an enterotoxin, cholera toxin (CT). An effective oral 
vaccine against V. cholerae O1 is available, whereas vaccine against O139 is lacking. 
Development and pre-clinical evaluation of cholera vaccines have been hampered by the fact 
that man is the only natural host for V. cholerae. Although various animal models have been 
described, there exists no convenient and inexpensive model that allows evaluation of 
vaccine-induced protection against a challenge infection.  
 
The main objective of this thesis was to develop a model that allows direct evaluation of the 
immunogenicity and protective efficacy of cholera vaccine candidates in conventional adult 
mice. Paper I demonstrates that strong serum and mucosal antibody responses to V.  cholerae 
O1 or O139 lipopolysaccharide (LPS) can be induced in adult mice vaccinated intranasally or 
orally with either live or formalin-killed bacteria. Standardized intestinal IgA antibody 
responses estimated using extracts prepared from faecal pellets or from intestinal mucosa 
were found to correlate significantly, hence validating the use of the more convenient fecal 
pellets extracts for measuring gut mucosal antibody responses in vaccinated hosts. Paper II 
describes an adult mouse model for studying intestinal colonization by V. cholerae and 
associated immune responses. It was shown that oral pre-treatment of mice with streptomycin 
(Sm) allows intestinal colonization by Sm-resistant V. cholerae O1 or O139 bacteria, and that 
mice immunized with viable or inactivated V. cholerae as described in Paper I were 
comparatively refractory to colonization following infection/challenge with the immunizing 
strain, with protection resulting in accelerated clearance of the challenge organisms 
correlating inversely with the intestinal IgA anti-LPS response. In paper III this model was 
further used to evaluate immune responses and protection by orally administered live and 
killed O1 and O139 whole cell vaccines and the impact of co-administration of CT on the 
immunogenicity and protective effect. CT proved to be an effective adjuvant, markedly 
potentiating antibody responses and also increasing the protective effect against both 
serogroup homologous and heterologous challenge. The results presented in this thesis 
suggest that the new adult mouse model may be used to broaden our understanding of 
immune protection against V. cholerae infection, and thus be a useful tool in the pre-clinical 
evaluation of oral cholera vaccines. 
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Abbreviations 
Ace  Accessory cholera enterotoxin 
ADP  Adenosine diphosphate 
ANOVA  Analysis of variance 
BSA  Bovine serum albumin 
C  Caecum 
cAMP  Cyclic adenosine monophosphate 
CFU  Colony forming units 
CPS  Capsule 
CT  Cholera toxin 
CTA  Cholera toxin A-subunit 
CTB  Cholera toxin B-subunit 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
ETEC  Enterotoxigenic Escherichia coli 
Fk  Formalin-killed 
FP  Faecal pellet 
FPE  Faecal pellet extracts 
GM  Geometric mean 
HRP  Horseradish peroxidase 
Ig  Immunoglobulin 
IMCM  Infant mouse cholera model  
IN  Intranasal 
IP  Intra-peritoneal 
KLH  Keyhole limpet haemocyanin 
Km  Kanamycin sulphate 
LB  Luria–Bertani 
LI  Large intestine 
LPS  Lipopolysaccharide 
LT  Heat-labile enterotoxin of E. coli 
MP  Membrane preparation 
OD  Optical density 
ORS   Oral rehydration solutions 
PBS  Phosphate buffered saline 
PERFEXT  Perfusion–extraction technique 
PF  Protection factor 
PMSF   Phenylmethylsulfonyl fluoride 
PO  Peroral 
RITARD  Reversible intestinal tie adult rabbit diarrhea model 
SD  Standard deviation 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SI  Small intestine 
Sm  Streptomycin sulphate 
SNs  Supernatants 
STI  Soybean trypsin inhibitor 
TCP  Toxin-coregulated pilus 
TcpA  Structural subunit of TCP 
TLR  Toll-like receptor 
VPI  Vibrio pathogenicity island 
WT  Wild type 
Zot  Zonula occludens toxin 
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Introduction 
 
Vibrio cholerae  
The diarrheal disease cholera is caused by the non-invasive Gram-negative curved rod 
bacterium now known as Vibrio cholerae. This organism was originally microscopically 
identified by Filippo Pacini in 1854. The role of V. cholerae in cholera disease was however 
not widely recognized until the rediscovery and isolation of the “comma-bacillus” by Robert 
Koch in 1884 (78, 85, 158). This polar monotrichous bacterium can, on the basis of the 
composition of the cell wall lipopolysaccharide O antigens, be classified into serogroups (see 
Table 1). Today more than 200 different serogroups have been described, yet for a long time 
only the O1 serogroup, and since 1992 also the O139 serogroup, are known to cause epidemic 
outbreaks (48). Importantly, strains of the O1 serogroup can also be biotyped as either 
classical or El Tor bacteria and further divided using serological methods into three subtypes, 
with names denoting their historical origin, Ogawa, Inaba and Hikojima (28). The later 
subtype is however rare and unstable (78).  
 
 
Table 1. General description of epidemic V. cholerae 
 
Serogroup Biotypes Serotypes TCP biotype Capsule 
O1 
El Tor Inaba or Ogawa El Tor 
na 
classical Inaba or Ogawa classical 
O139 na na El Tor Polysaccharides 
na, not applicable 
 
 
Cholera epidemiology 
Cholera continues to be an important cause of morbidity and mortality in several developing 
regions of the world, officially accounting for between 100,000 – 300,000 cases annually 
during the last ten years (2). However, the WHO recognizes that the disease is grossly 
underreported and that the actual number of cases may be 3-5 million per year, causing at 
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least 120,000 deaths (182). The disease is often associated with poverty, low socioeconomic 
status, overcrowding and malnutrition (54, 182). Children under 5 years of age living in 
endemic areas and persons of blood group O are also at higher risk of developing severe 
cholera when infected (31, 42, 47). Studies by Clemens et. al. (31), conducted in Bangladesh 
at a time when the classical and El Tor biotype were cocirculating and causing similar 
numbers of disease, have revealed that the link between blood group O and severity of disease 
was only valid for V. cholerae O1 El Tor infection. Later, during the emergence of V. 
cholerae O139 it was observed that individuals of blood group O are also more susceptible to 
O139 infection than those with other blood groups (47). 
 
V. cholerae appear to have relatively simple nutritional requirements for survival outside the 
human body, as indicated by the observation that the bacteria is normally found in surface 
water of various aquatic environments (50, 177), such as the Gulf of Mexico, the costal 
regions and fresh water reservoirs of many African countries and most importantly in the 
Ganges river; the later area being the endemic homeland for V. cholerae (78, 133). It is known 
that cholera has existed in the Indian subcontinent since the beginning of records and that the 
disease since at least 1817 has spread outside this area, causing seven distinct pandemics. The 
6th pandemic and possibly also the 5th pandemic were caused by classical V. cholerae O1 
strains (48, 111), whereas the current 7th pandemic is caused by strains of the El Tor biotype. 
In contrast to the previous pandemics the latest and still ongoing pandemic began in Indonesia 
on the island of Sulawesi (formerly known as Celebes) in 1961 (17). The El Tor biotype was 
however originally isolated by Felix Gotschlich already in 1905 from Indonesian pilgrims to 
Mecca, at the quarantine station in El Tor, Egypt (133). During the 1960’s El Tor bacteria 
spread to most countries in South-East Asia where it, except for a brief period in time, 
displaced the classical strains totally (94, 138). During the early 1970’s it continued to spread 
from Asia to the Middle East and also to sub-Saharan West Africa (54). In January 1991 
cholera returned to South America for the first time in a century, causing epidemic outbreaks 
in Peru and soon thereafter affecting almost all countries in South America, where it is now 
endemic (182).  
 
In 1992-1993 a second serogroup (O139) with epidemic potential emerged in India and 
southern Bangladesh (7, 112). Several investigations have suggested that V. cholerae O139 
arose from an O1 El Tor strain by acquisition of DNA coding for the synthesis of the 
antigenically-determining (serogroup specific) O antigen (19, 159). Since this new serogroup 
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initially displaced the current V. cholerae O1 strains and also in the following years spread to 
several Asian countries (3, 7, 112), it was feared that this new organism may cause an 8th 
cholera pandemic in parallel to the ongoing 7th V. cholerae O1 El Tor pandemic. Although 
recent data have shown that V. cholerae O139 today exists side by side with O1 strains in 
India and Bangladesh, occasionally giving rise to epidemic outbreaks (49, 152), V. cholerae 
O1 El Tor is still the predominant cause of cholera world-wide accounting for more than 95% 
of all cases (182). Yet, based on the experiences with the El Tor biotype, which more than 50 
years after its first isolation started a large pandemic, the risk that O139 may become 
pandemic remains. 
 
Most recently it has become evident that different variants of V. cholerae O1 El Tor 
producing CT of the classical biotype are circulating in Bangladesh, India, Mozambique and 
Vietnam (9, 10, 58, 106, 111). It has further been shown that since 2001 only El Tor strains 
expressing CT of the classical biotype have been isolated in Bangladesh (111). Similar 
findings have also been made for the O139 serogroup (J. Sanchez and J. Holmgren, 
unpublished). Intriguingly the shift in CT expression profile appears to have caused the 
bacteria to become more virulent (111, 168), although solid evidence is still missing.  
 
Clinical features 
Cholera is a disease of the small intestine. Following ingestion of toxogenic V. cholerae and 
successful colonization of the intestinal mucosa the bacteria effectively release cholera toxin, 
which via its high affinity interaction with the monosialoganglioside GM1 on the intestinal 
epithelium is endocytosed. Subsequently CT activates adenylate cyclase inside the epithelial 
cells and induces a cascade reaction which ultimately gives rise to the characteristic profuse, 
and sometimes life-threatening, diarrhea and dehydration. In addition to CT, there are also 
several “minor toxins” which contributes to the pathogenicity of V. cholerae, as indicated by 
the observation that attenuated live cholera vaccines unable to produce CT still are able to 
cause diarrhea in healthy volunteers (91, 165). Although the colon is also affected by CT, it 
has been estimated that approximately 90% of the secreted fluids originate from the small 
intestine (67, 133). In contrast to what was originally described by Robert Koch (85), V. 
cholerae does not normally disrupt the intestinal epithelium, hence the resulting diarrheal 
fluid contains only minor amounts of protein and blood cells (67, 78). Instead the volumes 
stools contain large amounts of sodium, chloride, bicarbonate and potassium (133). In severe 
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cases (cholera gravis) continuous diarrhea, if untreated, often results in hypovolemic shock 
and collapse after only a few hours. Death can occur already 12 hours after onset of disease 
(133), making cholera a much feared infectious disease. A large proportion of V. cholerae 
infections do however remain inapparent and do not result in severe disease (78, 104, 126, 
149).  
 
The incubation period and the severity of disease appear to be effected by the size of the 
inoculum (78, 108). Whereas the infectious dose to cause severe cholera in healthy adult 
volunteers has been shown to be ca. 108 bacteria (78, 133), malnourished, hypochlorhydria 
and immunodeficient individuals has been shown to be more prone to develop disease (134, 
180), with doses as low as 103 bacteria commonly being cited (78, 133) . If the bacteria is 
ingested together with food or other agents with the capacity to neutralize the gastric acidity 
e.g. bicarbonate, the minimal pathogenic dose is decreased significantly; with 106
 
 vibrios 
being able to induce diarrhea in 90% of volunteers (67, 72). 
Although V. cholerae clearly spreads via the faecal-oral route, direct person-to-person spread 
is probably less common than ingestion of contaminated water or food (128). V. cholerae 
passaged through the human intestine has recently been found to be more infectious in infant 
mice than in vitro cultured bacteria (105). This transient hyper infectious phenotype may be 
one mechanism that contributes to the explosive outbreaks of cholera often seen during 
epidemics. Another such mechanism by which V. cholerae increases its spread during 
epidemics may be the capability to cause inapparent infections, leading to dissemination of 
bacteria for an extended period of time following infection (83). 
 
Patients with severe cholera may require intravenous fluid rehydration, especially when the 
rate of fluid loss by diarrhoea exceeds that of what can be compensated by oral rehydration. 
However, most cases of cholera can be successfully treated with simple oral rehydration 
solutions (ORS), containing both salts and glucose (133). When properly administered the 
ORS can decrease the cholera case fatality rate to below 1% even in developing countries (2). 
Although effective antibiotic treatment can be used to shorten the duration of cholera disease 
and decrease the risk for further spread of the infection, the WHO only recommends treatment 
with antibiotics in severe cases of cholera. Due to uncontrolled use of antibiotics in several 
cholera-struck regions, numerous pathogenic V. cholerae strains are today resistant against 
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some of the most common antibiotics on the market, including Streptomycin, Trimethoprim, 
Kanamycin, Ampicillin, Gentamycin and Tetracycline.  
 
Despite the high rate of inapparent infections and the efficacy and simplicity of treatment, the 
annual morbidity/mortality toll in developing regions of the world means that vaccine 
research is warranted. 
 
Pathogenicity and virulence factors 
Studies of the processes occurring in the intestine after ingestion of pathogenic V. cholerae 
O1 or O139 have shown that those vibrios that do survive passage through the acidic stomach 
rely on temporal expression/action of several different secreted and cell-associated 
components for colonization of the intestinal mucosa and subsequent induction of cholera 
disease. Most important for the colonization, which is a prerequisite for production of CT, is 
1) the sheathed polar flagellum, 2) the mucinase (soluble hemagglutinin) and 3) the toxin-
coregulated pilus (TCP). The former two are thought to be involved in the early phase of 
colonization and TCP in the late phase. In addition it appears that LPS also plays an important 
role (28, 67, 78). 
 
The key virulence factors of V. cholerae are encoded in two distinct areas on chromosome I of 
the bacteria, the CTX element and the vibrio pathogen island (VPI). Both of these elements 
are believed to originate from different bacteriophages (39, 139). The CTX element is the 
genome of an integrated filamentous phage, CTXΦ and contains the genes encoding the 
cholera toxin (173). Importantly the receptor for CTXΦ has been shown to be TCP, which in 
turn is encoded in the VPI island (79, 80, 86). Studies by Boyd and Waldor have however 
suggested that the bacteriophage CP-T1 provides an alternative TCP independent mechanism 
for horizontal transfer of CTXΦ between pathogenic and non-pathogenic V. cholerae strains 
(23). In addition, there are also virulence determinants that are located outside the CTX and 
VPI elements, LPS probably being the most important (7). 
 
CT 
Undoubtedly, cholera toxin is one of the more potent bacterial toxins known to man; capable 
of causing severe diarrhoea even with doses as low as 5-10 µg (89). The existence of this 
enterotoxin was first postulated by Rober Koch and later separately identified independently 
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by both De and Dutta in 1959 (40, 45). A few years later it was shown that CT is a complex 
protein consisting of one A subunit (28 kDa) and five B subunits (11.6 kDa each) in a ring 
(95). Following colonization the bacteria upregulates the genes encoding CT (ctxAB) and 
express CT which after assembly in the periplasm, via a so-called type II secretion system, is 
efficiently, transported across the outer membrane and released into the surroundings. The 
excreted toxin binds to GM1 ganglioside receptors on the intestinal epithelium via the non-
toxic B-pentamer (69), which allows for the toxin to be internalised (139). Following 
proteolytic cleavage of the CTA into its CTA1 and CTA2 parts, the former becomes active. 
The CTA1 component then activates adenylate cyclase by catalysing the ADP-ribosylation of 
CTP-binding regulatory component of the cyclase system. Subsequently, abnormal levels of 
intracellular cyclic adenosine monophosphate (cAMP) accumulates and modulates electrolyte 
and fluid transport across the epithelium. It is generally accepted that the volumes diarrhea 
results from increased active anion secretion, mostly chloride and bicarbonate, in combination 
with simultaneous inhibition of sodium absorption. These processes result in increased 
sodium outflow, and drives water secretion which gives rise to the characteristic cholera 
diarrhea (67, 78, 139). The heat labile toxin (LT) of enterotoxigenic E. coli (ETEC) has been 
shown to function similarly to CT in many aspects (140). Importantly the toxic effects of both 
CT and LT can be antagonized by cross-reacting antibodies to the B-subunit (70). 
 
TCP 
The toxin-coregulated pilus (TCP) is a homopolymer of repeated subunits of the major pilin 
component TcpA, similar to other enterobacterial type 4 pili (170). V. cholerae O1 El Tor and 
O139 bacteria produce a closely related pilli, whereas bacteria of the classical biotype 
produce an antigenically dissimilar pili (77, 129, 181). Studies initially performed in infant 
mice showed that mutants unable to express TCP are incapable of colonizing the intestinal 
epithelium (13, 170). When wild-type V. cholerae were mixed with mutant bacteria unable to 
express TCP and fed to infant mice, the mutants were found to be outcompeted with regards 
to the number of colonizing bacteria, giving rise to a very high competition index (13). These 
findings have also been confirmed in human volunteer challenge studies (65, 167).  
Although the exact role of TCP in colonization is not fully understood, it has been suggested 
that there might exist an intestinal receptor for TCP (84). However, reports have also shown 
that TCP promotes bacterial interaction and that the pilli is crucial for microcolony formation 
(84, 93, 170). These results do however not contradict each other and the function of TCP in 
colonization may be multifactorial.  
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The V. cholerae flagella 
The polar flagellum of V. cholerae is partially covered by a protrusion of the LPS containing 
outer membrane (53). The function of the flagella is complex, contributing to the motility of 
V. cholerae by operating together with chemotactic receptors and intracellular sensor 
molecules (20). Most likely the flagella contributes to the patogenicity of the bacteria by 
mediating some of the initial steps of colonization (15). Directed motility towards the 
intestinal cell wall by V. cholerae has been shown to depend on the propelling movement of 
the polar flagella and deletion of genes encoding the sodium-driven flagella motor proteins 
results in flagellated but non-motile bacteria (20). Human volunteer trails conducted with 
attenuated live cholera vaccine candidates have suggested that the reactogenicity observed 
with most attenuated V. cholerae strains are at least partially caused by flagella driven 
motility (82). Importantly it was shown by Taylor et al. (169), that infection with high doses 
of a filamentous motility-deficient mutant V. cholerae O1 El Tor (Peru 14), originally 
identified to have reduced capacity to move in soft-agar, produced only marginal 
reactogenicity in a volunteer study. Studies performed using different animal infection models 
to compare V. cholerae strains with various combinations of defined motility and/or structural 
mutations have also demonstrated that motility is an important component of V. cholerae 
colonization and pathogenicity in experimental cholera (87, 130). Further, it has been shown 
that flagellin, the major component of the inner structure of the flagella, can induce 
inflammatory responses via TLR5 (63). The exact role for the flagella in colonization and 
virulence of V. cholerae O1 El Tor and O139 strains is however not very well understood (20, 
153). 
 
Mucinase (soluble hemagglutin) 
The soluble hemagglutinin, which is encoded by the hapA gene, is one of several 
hemagglutinins produced by V. cholerae O1 of both biotypes and O139 (64). The soluble 
hemagglutinin (or HapA and HA/protease) is a secreted zinc-dependent protease (22, 153) 
that has been shown to cleave several mucus associated components including mucin, 
fibronectin and lactoferrin (51). Translocation of V. cholerae through mucin-containing gels 
has also been shown to required expression of hapA (155). In addition it has also been shown 
to be involved in the activation of the cholera toxin A-subunit (21). Further, the soluble 
hemagglutinin is also excreted via the same general secretion pathway as CT (141). These 
findings fit well with the idée that the initial phase of V. cholerae colonization most likely 
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depends on the capacity of the bacteria to penetrate the intestinal mucus layer (153). In 
contrast to findings in infant mice and rabbits, safety and immunogenicity studies with an 
attenuated cholera vaccine candidate V. cholerae 638, lacking the CTXΦ and also hapA have 
recently indicated that the soluble hemagglutinin contributes to the pathogenicity and adverse 
effects often observed with live attenuated cholera vaccines (55, 153)   
 
Other virulence factors of V. cholerae 
In addition to CT and mucinase, V. cholerae also produce several other soluble factors with 
pathogenic potentials. Among these are the Accessory cholera enterotoxin (Ace); Zonula 
occludens toxin (Zot) which might be both a morphogenetic phage protein and an enterotoxin; 
the pore-forming and vacuolating hemolysin A, the S-CEP (Chinese hamster cell elongating 
protein) cytotonic protein; and the actin-crosslinking RTX toxin (67, 78, 142). Although these 
factors have been suggested to singly or jointly contribute to some of the adverse reactions 
observed with live attenuated cholera vaccines, the importance of these factors in human 
disease remains some-what unclear (91, 166, 169). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cell walls of V. cholerae O1 and O139, similarly to other Gram-negative bacteria, 
contains both protein structures and LPS which interact with the host and facilitates 
pathogenicity (28, 78). The LPS of V. cholerae is a highly immunogenic and retains this 
property after both heat and formalin treatment (28, 162). The genes encoding the 
biosynthesis of LPS are located on chromosome 1 of V. cholerae and give rise to the 
Fig. 1. Schematic structure of V. cholerae lipopolysaccharide.  
* The number of monosaccharide repeating units of the O-PS is 
variable between V. cholerae serogroup O1 (n = 12-18) and O139 
(n = 1). 
 
Lipid-A Core-PS O-PS (n*)
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characteristic polysaccharide structure consisting of the lipid-A, core-PS and O-PS (see 
Figure 1). The core-PS and O-PS parts project outward from the bacteria while the lipid-A 
region of LPS is attached to the outer membrane (27). In addition to its general function in 
preventing bile salts and other bactericidal molecules found in the intestine, LPS may also be 
directly involved in gut colonization, as indicated by the observations that the O-PS is 
important for intestinal colonization in infant mice (11, 172). Further, it has also been shown 
in vitro that attachment of V. cholerae to a monolayer of mucin-secreting cells can be partially 
inhibited by the addition of LPS (18).  
 
The apparent lack of cross-protection between V. cholerae O1 and O139, observed during the 
emergence of the O139 serogroup in 1992 to 1993, also stresses the importance of the O-
antigens for pathogenicity (7, 126, 133). In the years following after the emergence of V. 
cholerae O139, it was shown that the O139 O-PS lack perosamine, a characteristic sugar 
found in V. cholerae O1 of both El Tor and classical biotype; and that the O-PS of O139 
consists of only one subunit instead of several, as in the O1 serogroup (27, 126). In addition to 
the LPS, V. cholerae O139 similarly to several other non-O1 vibrios also produce a capsule 
consisting of polymerized O-antigen subunits (CPS), that are antigenically very similar 
underlying O-PS  (27, 126). Functional studies of the role of the capsule have suggested that 
presence of CPS contributes to virulence by decreasing the sensitivity to serum killing and by 
increasing binding to intestinal epithelial cells (76, 172). More recent studies have suggested 
however, that production of O-antigen by O139 strains is of greater importance than the 
presence of CPS material for virulence (11).  
 
Outer membrane proteins (Omps) of V. cholerae have been implicated to participate in 
bacterial interactions in the host intestinal milieu. Although TCP and the flagellum are major 
components of these interactions, immune sera collected following vaccination or infection 
with V. cholerae also recognize other non-LPS antigens (38, 147, 156). Some of these 
immunogenic proteins have also been observed to be protective antigens in experimental 
cholera models, such as OmpU (38-42 kDa) and OmpW (19-22 kDa) (38, 148, 156). A so 
called ”cholera protective antigen” (18 kDa) has also been suggested to contribute to 
protection against experimental cholera (145).  
 
Studies the mannose-sensitive hemagglutinin (MSHA, 17 kDa) which is expressed on V. 
cholerae O1 El Tor and O139 but not on classical bacteria, have shown that even though this 
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pilus is immunogenic (122, 124), monoclonal antibodies to MSHA do not protect infant mice 
against V. cholerae infection (13). Importantly, a human volunteer vaccine study with a 
MSHA deficient V. cholerae O139 strain CVD 112 have also failed to prove a role of this pili 
in colonization of the human intestine (167). The function of MSHA is probably instead 
related to its persistence in aquatic environments (74, 175). Further, it has also been suggested 
that repression of MSHA expression following infection is important for avoiding IgA 
mediated blocking of V. cholerae colonization, in a mannose-sensitive, non-antibody specific 
manner (73, 74). 
  
Immunity to cholera 
Protection against cholera is most likely a combination of adaptive immune responses elicited 
by previous infection or vaccination and innate immune mechanisms. Little is however known 
about the latter. Recently though, whole-genome microarray studies conducted on duodenal 
biopsies collected during the acute phase of the infection, have shown broad upregulation of 
genes known to be involved in innate immunity (60). This observation is in line with findings 
by Qadri et al. (52), showing increased numbers of neutrophil polymorphs in the lamina 
propria and upregulation of several innate 
 
mediators e.g. myeloperoxidase, lactoferrin and α-
defensin in adults suffering from acute watery cholera diarrhea. 
Infection with V. cholerae O1 or O139 can induce lasting protective immunity against re-
infection, especially if severe enough to cause clinical disease (108, 121). The nature of this 
protective effect has been well studied and there is abundant evidence that along with CT, V. 
cholerae lipopolysaccharide is the predominant protective V. cholerae antigen (56, 67, 88). 
Serological studies utilizing the bactericidal assay, which measures the ability of antibodies to 
kill V. cholerae in the presence of complement, have shown that vibriocidal antibodies 
increase with age in areas where V. cholerae is endemic and that the attack rate is inversely 
related to the vibriocidal antibody titre (34, 88, 164). Although a minor proportion of the 
vibriocidal response may be directed against outer membrane proteins, the major component 
of the response is immunoglobulin M directed against serotype specific LPS (57, 97, 109, 
110, 113). The large epidemic outbreaks of V. cholerae O139 during 1992 to 1993 in India 
and Bangladesh, where the El Tor biotype at that time was endemic (12, 97, 114), further 
illustrates that acquired immunity to LPS is of utmost importance for protection against 
disease. Despite the fact that V. cholerae O1 El Tor and O139 share several characteristics 
- 17 - 
and produce identical CT and TCP (3, 7, 112), the epidemic outbreaks of V. cholerae O139 in 
1993 were distinguished by an unusually large proportion of infected adults (5, 129).  
 
Even though serum vibriocidal antibodies induced by infection or oral immunization is the 
best known predictor for protection against disease caused by V. cholerae (3), these antibody 
responses are most likely surrogate markers for immunity to cholera. Importantly, there exists 
no threshold vibriocidal titre above which a person is protected against developing 
symptomatic cholera (35, 109, 164). Secondly it is also known that even though parenteral 
cholera vaccines elicit very high serum vibriocidal titres, such vaccines only confer short-
lived (6 months) and limited protection (around 50%) (62, 137). More likely, protection 
against disease induced by infection or vaccination results from a broader gut derived IgA 
immune response to V. cholerae (16, 59, 62, 124). 
 
Several studies in experimental cholera models have convincingly shown that intestinal 
synthesis of IgA antibodies to CT are protective (62, 67, 71, 150). Importantly the CTB 
component by itself also has the capability to induce strong protection against experimental 
cholera (119, 120, 161), and to provide about 60% cross-reactive protection for 6 months 
against diarrhea caused by heat labile toxin (LT) producing enterotoxigenic E. coli (ETEC) 
(33).  
 
Serum IgA, but not IgG, antibodies to CTB have also recently been found to predict 
protection against V. cholerae O1 El Tor infection in a cohort household study (62). This 
study also shows that serum antibodies to TCP, which can been found in approximately half 
of all tested individuals previously infected with V. cholerae (16, 61), are also associated with 
protection against both V. cholerae O1 and O139 (62). Although antibodies to TCP are 
sufficient to protect infant mice from colonization by V. cholerae (151, 160), direct protection 
induced by TCP remains to be de demonstrated in humans. 
 
Vaccines against cholera 
Following the initial attempts by Jaime Ferrán in 1884 to vaccinate against cholera using 
ordinary broth cultured V. cholerae, several vaccines against cholera have been developed 
(59). A parenteral cholera vaccine containing a mixture of killed whole cell V. cholerae O1 of 
different serotype and biotype is still available in some countries. However, this type of 
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vaccine does not only provide limited and short-lived protection (around 50% for less than six 
months), but are also associated with frequent adverse reactions (50% local reaction and 30% 
general) (59). For these and other reasons WHO does not recommend the use of any 
injectable vaccine. Instead WHO recommends the use of oral cholera vaccines (OCV) in 
certain endemic and epidemic situations (67). Two principally different types of oral cholera 
vaccines have been licensed for wider use in humans: 1) a killed whole cell oral vaccine with 
or without the nontoxic B-subunit of cholera toxin and 2) an attenuated live oral vaccines (59, 
67); however only the first type is currently available on the market. 
 
Killed whole cell oral vaccines 
As a result of several studies on the immunogenicity and protective effect of purified CTB 
and also killed V. cholerae administered orally, the DukoralTM whole cell cholera vaccine was 
developed during the 1980s (66). The present vaccine consists of 1 mg of purified 
recombinant CTB in combination with 2.5 x 1010 killed V. cholerae O1 El Tor (Inaba) and 
Classical (Inaba and Ogawa) bacteria (96). The protective efficacy of the DukoralTM vaccine 
has in two studies carried out in Bangladesh and Peru been shown to be ca. 85% for six 
months (67). Recently the vaccine was also administered to a large population in 
Mozambique with a high seroprevalence of HIV infection without markedly reducing its 
efficacy (98). In long term studies of DukoralTM vaccinated individuals in Bangladesh, the 
protective efficacy against cholera after three years has also been shown to be about 50% 
(174). Importantly the added CTB component has also been shown to have a synergistic 
protective effect together with the whole cell component, increasing the protective efficacy of 
the vaccine significantly during the initial eight months of observation (30, 32). DukoralTM 
has also been found to function well as a travelers’ vaccine if two doses are administered prior 
to departure (143), and further to give rise to heard protection (20). Currently the DukoralTM
 
 
vaccine is produced by Crucell (formally SBL vaccines) and licensed in more than 50 
countries (67). 
Technology transfer from Sweden has also allowed for a simplified V. cholerae O1 vaccine 
lacking the CTB-component to be produced and licensed in Vietnam (67, 96). More recently, 
production of the Vietnamese cholera vaccine has been improved and the composition altered 
so that it now also contains killed V. cholerae O139 bacteria (8). Noteworthy, the 
reformulated vaccine contains almost 40% more LPS antigen as compared to the earlier 
Vietnamese vaccine (103). Following successful phase II studies with this bivalent 
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formulation, the production technique is currently being transferred from Vietnam to WHO-
approved facilities in India and Indonesia. A large phase III placebo-controlled, randomized 
trail undertaken in Kolkata, India, with support from the International Vaccine Institute (IVI) 
is also currently being evaluated.  
 
CVD 103-HgR and other attenuated live oral cholera vaccines 
Several different live attenuated V. cholerae strains lacking at least the A-subunit of CT have 
been developed as vaccines against cholera. One of these strains CVD 103-HgR (OracholTM
 
) 
has also been licensed in a few countries for use in travelers to endemic areas (67). Orochol is 
based on the V. cholerae O1 classical Inaba strain 569B and has been genetically detoxified to 
contain only the B-subunit of CT. A mercury resistance gene has also been introduced into the 
hemolysin locus, allowing for this strain to be easily identified in environmental samples (90). 
CVD 103-HgR has been shown to be safe and immunogenic in many studies, eliciting strong 
antibacterial responses with only a single dose (96). The protective data are however some 
what contradictory. Vaccination with this classical strain has been shown to provide 
protection in US volunteers against later challenge with V. cholerae O1 El Tor (163), but a 
large double-blind, placebo-controlled field trial carried out in Indonesia with CVD 103-HgR 
unfortunately failed to show significant protection during the four-year observation period 
(13.5% overall efficacy) in a cholera-endemic setting (132). Yet, a retrospective study of a 
vaccination campaign in Micronesia, carried out as part of a cholera outbreak response, 
estimated the vaccine efficacy of CVD 103-HgR to be 79% (25). Importantly this vaccine 
does not appear to be protective against V. cholerae O139 (6). Production of the CVD 103-
HgR vaccine was halted in 2004 (1, 96). 
In addition to the CVD 103-HgR, a handful of attenuated live El Tor vaccines (Peru 15, CVD 
110, IEM101 and V. cholerae strain 638) or O139 vaccines (Bengal 15 and CVD112) are 
currently in various states of clinical evaluation (67). Although these live attenuated vaccines 
are highly immunogenic most have also been reported to elicit reactogenic responses or at 
least mild diarrhea (142).  
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Cholera toxin as immunomodulator 
In addition to the enterotoxic effects of CT and LT, these toxins are highly immunogenic and 
also remarkable adjuvants. The immunomodulatory property of CT was initially observed 
using the systemic route of immunisation (68, 81). When CT a few years later was given 
orally to mice together with keyhole limpet haemocyanin (KLH) it was observed that the 
intestinal IgA antibody response to KLH was significantly potentiated, indicating that CT was 
also an adjuvant for unrelated antigens delivered mucosally (46). Later studies confirmed 
these findings and also revealed a critical temporal effect of CT-administration on intestinal 
antibody formation (100, 139), simultaneous administration of CT and KLH giving rise to the 
strongest responses.    
The adjuvant effects of CT and LT observed following administration into the intestinal tract 
has been suggested to largely depend on the fact that these toxins are remarkably resistant to 
degradation by proteases, bile salts and other compounds in the intestine; bind with high 
affinity to GM1 ganglioside receptors, which are highly expressed on intestinal epithelial cells 
as well as on the M-cells of lining the Peyers patches; and stimulates uptake of co-
administered antigens by increasing permeability of the intestinal epithelium leading to 
enhanced accessibility for antigen-presenting cells (139, 140). On the cellular level, CT and 
LT enhances antigen presentation by various antigen presenting cells, promotes isotype 
switching to IgA in B-cells, and modulates complex stimulatory as well as inhibitory 
pathways regulating T-cell proliferation and cytokine production by both innate and adaptive 
immune cells (99, 139, 140, 142). Although the adjuvanticity of CT and LT mainly resides in 
the enzymatic activity of the A1 component, the underlying mechanisms are not yet fully 
understood (127).  
 
Animal models for intestinal V. cholerae infection and disease 
V. cholerae is a strict human enteropathogen, the adults of no other species being naturally 
susceptible to infection (26, 41, 44, 157, 171). All animal models in adult hosts are therefore 
unnatural in one way or another, often requiring chemical, antibiotic and/or surgical 
manipulations. Yet, information obtained from various animal cholera models has been found 
to predict the outcome of several human infection and protection studies (131). 
 
The pioneering work by De et al. (40) in the identification of the cholera toxin was performed 
using the rabbit ligated intestinal loop model (41). False-positive results are however not 
- 21 - 
uncommon with this model. Several other animals, for example rats, mice and chickens, have 
been similarly treated and used for studies of the secretory response of CT  (131). Importantly 
studies using the mouse ligated loop assay have provided direct evidence for the importance 
of intestinal IgA in protection against CT (161). The Removable Intestinal Tie Adult Rabbit 
Diarrhea (RITARD) model developed by Spira et al. (157), has also been of great importance 
for studies of induction as well as protection against lethal watery diarrhea (101, 130). 
Similarly to the ligated loop assays this model does require surgical manipulation prior to 
challenge i.e. ligation of the small intestine with a slip knot tie directly proximal to the 
caecum. Two hours after inoculation the tie is removed and the rabbits are monitored for 
diarrhea and lethality, usually occurring within a few days in unimmunized animals infected 
with V. cholerae (131, 157). An alternative to these invasive models is the canine cholerae 
model of Sack and Carpenter (135) which do not require any surgical work. Despite the 
usefulness and reproducibility of this model it is not commonly used because of the high cost 
and more rigid animal care associated with it. 
 
Much less expensive are infant (or suckling) mice, which following oral infection with V. 
cholerae bacteria do become intestinally colonized. This model, originally developed by 
Ujiiey et al. (171), is commonly used for competition experiments between wild type (WT) V. 
cholerae and mutant bacteria expressing some sort of marker that allows identification. 
Important information about the relative significance of TCP and MSHA for colonization was 
obtained using this model (13). Other very young animals such as infant rabbits can also 
readily be colonized with V. cholerae (44). However, these models are limited by their 
immunological and physiological immaturity. Yet studies of passive immunity have 
successfully identified antigenic targets which can block colonization (151, 160). As these 
animals become older and acquire an intestinal bacterial flora they do however rapidly 
become refractory to colonization.  
 
In contrary to conventional mice, adult gnotobiotic mice can also become colonized with V. 
cholerae (24). Although such mice have been used occasionally to study acquired immunity 
to different antigens expressed by V. cholerae (37), the usefulness of this model has been 
questioned. Not only is the intestinal immune system in germfree mice relatively immature, 
their handling and housing is also costly (102, 107).  
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Aims of this study 
 
The general aim of this thesis was to develop a model that will allow direct evaluation of the 
immunogenicity and protective efficacy of cholera vaccine candidates in conventional adult 
mice. 
 
The specific aims were: 
 
• To define immunization protocols for viable and killed V. cholerae which consistently 
elicit both systemic and mucosal antibacterial antibody responses. 
 
• To evaluate the validity of using faecal pellet extracts for assessment of intestinal antibody 
responses. 
 
• To define protocols for establishing intestinal V. cholerae O1 and O139 colonization in 
streptomycin treated adult mice 
 
• To examine if vaccinated hosts are comparatively refractory to colonization following 
challenge with V. cholerae. 
 
• To evaluate the impact of co-administration of cholera toxin on vaccine-induced antibody 
responses and protection. 
 
• To examine correlates of immunity with protection against colonization. 
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Materials and methods 
 
Bacterial strains and culture conditions 
V. cholerae strains used in this thesis (See Table 2) were stored at -80°C in Luria-Bertani 
(LB) medium containing 20% glycerol, and grown in LB at 37 °C with agitation (150 rpm). 
When necessary for in vivo studies, Sm-resistant variants were selected by growth on LB agar 
plates containing Sm (200 µg/ml). For immunization or challenge of mice, bacteria were 
grown to OD600
 
 1.0-1.2, harvested by centrifugation and washed twice in PBS before use. 
Wild-type V. cholerae strains H1 and N1696 are of O1 serogroup (biotype El Tor, serotype 
Ogawa and Inaba respectively), while JBK70 is an atoxigenic mutant of the latter (91). MO10 
and AI-1838 are encapsulated serogroup O139 isolates. AF3 is an unencapsulated variant 
derived from AI-1838 (11) which was used for isolation of O139 LPS. A tcpA::Km 
(kanamycin) derivative of AI-1838 (13) was used to investigate the role of TCP in 
colonization.  
Table 2. Presentation of V. cholerae strains and their variants used in this thesis 
 
Parent strain Serogroup Serotype Biotype Variants 
H1 O1 El Tor Ogawa WT tcpA::KmR mutant 
N16961 O1 El Tor Inaba WT 
∆ctx (JBK 70) 
MO10 O139 na na WT* 
AI-1838 O139 na na 
WT* 
tcpA::KmR mutant 
Unencapsulated (AF3) 
na, not applicable 
*, encapsulated 
 
 
Formalin-inactivation of V. cholerae 
Vibrio cultures grown and harvested as above were washed twice with PBS and resuspended 
to a final concentration of 1010 cells/ml in 1% formaldehyde-PBS. Following incubation at 
37°C for 2 hours the cells were washed twice and resuspended in PBS. Aliquots were plated 
to confirm sterility before addition of sodium azide and storage at 4°C. Formalin-killed (fk) 
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bacterial suspensions were enumerated using a Neubauer Improved cell counting chamber 
(0.02mm, Neubauer, Germany) and used within 14 days of preparation. Prior to immunization 
the suspension was again washed twice in PBS and resuspended to the desired concentration.  
 
Isolation of V. cholerae antigens 
LPS was extracted from V. cholerae O139 strain AF3 (11) using the phenol–water method of 
Westphal and Jann (176). After phenol extraction crude preparations were treated with 
Deoxyribonuclease I (Sigma-Aldrich D5025; 0,4 mg/ml) and Ribonuclease A (Sigma R5000; 
0,4 mg/ml) in Tris/HCl-buffer (20 mM, pH 8.0) containing MgCl2 (1 mM) and NaCl (10 
mM) for 24 h at room temperature (RT); followed by treatment with Proteinase K (Sigma 
P8044; 2% w/w) in Tris/HCl-buffer (20 mM, pH 8.0) containing CaCl2
 
 (1 mM) for 24 h at 
RT. After a second phenol-water extraction, the preparation was dialyzed extensively against 
distilled water and then lyophilized. Protein contamination was < 1% as judged by Micro 
BCA Protein Assay Kit (Pierce Biotechnology) and by optical density at 280 nm relative to 
total weight. V. cholerae O1 LPS (Inaba 569B) was purchased from Sigma Aldrich (L-0385) 
and described as having <3 % protein contamination. Membrane proteins from V. cholerae 
O1 strain JBK70 was prepared as described previously (4). Briefly, the bacteria were 
sonicated and subjected to low-speed centrifugation to remove intact bacteria. Cell 
membranes were pelleted by centrifugation (30 min at 10k x g), resuspended in PBS and 
optically quantified as above. 
Animals 
Female BALB/c, C57BL/6, C3H/HeN, SJL and CD1 mice were purchased from Charles 
River Laboratories (Sulzfeld, Germany), provided food and water ad libitum, individually 
marked and generally used one week after delivery at the age of 8 weeks. In a few 
experiments mice of younger ages were used in competition studies (se below). All animals in 
this study were treated and housed under specific-pathogen free conditions at the Laboratory 
for Experimental Biomedicine at University of Gothenburg as stipulated by the Ethical 
Committee for Laboratory Animals in Gothenburg. 
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In vivo experiments with V. cholerae 
a) Immunization with viable or inactivated V. cholerae 
Mice were immunized without any prior antibiotic treatment. IN immunization was 
performed by administering 10 µl of bacterial suspension (prepared as described above in 
LB), dropwise to the external nares of each animal using an air displacement pipette. Mice to 
be immunized either intragastrically or intraperitoneally (IP) were lightly anaesthetized with 
isoflurane (Isoba vet, Schering-Plough Animal Health, Stockholm). For IP immunization, 
mice were injected with 200 µl bacterial suspension (prepared as described above in PBS). 
Immediately prior to intragastrical inoculation, refered to as peroral (PO) immunization 
throughout our studies, the bacterial suspension was mixed with an equal volume of 1 M 
NaHCO3
 
 in LB, then 200 µl was administered using a 1 ml syringe and a disposable feeding 
needle with silicon tip (Fuchigami Ltd., Kyoto, Japan). When immunizations were performed 
with viable V. cholerae, the number of bacteria (CFU) administered to the animals was 
determined retrospectively by plating suitable dilutions of the suspensions onto LB-plates. In 
all experiments additional age-matched mice were set aside as untreated controls. 
b) Infection/challenge with viable V. cholerae 
Naïve or immunized mice were treated with Sm prior to challenge with pathogenic V. 
cholerae. Animals were provided with Sm-containing water ad libitum according to schedules 
described in the figure legends. Dosing was performed as described for PO immunization 
above; the number of viable bacteria administered was estimated retrospectively by viable 
counting. 
 
c) Estimation of in vivo colonization 
The duration and intensity of V. cholerae colonization was generally estimated by monitoring 
excretion of bacteria in freshly-collected faecal pellets (FPs). Four FPs (ca. 0.07 g) were 
collected into 1 ml of ice-cold PBS, homogenized and plated in serial dilutions onto agar 
plates containing Sm. Initially collection tubes were weighed prior to and after collection of 
FPs, to allow calculation of CFUs per mg faecal material, but this did not significantly alter 
the data and was deemed unnecessary.  
In some experiments additional mice were infected to allow enumeration of bacteria 
persisting within the small intestine (SI), caecum (C) and large intestine (LI). Tissues were 
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extensively rinsed in ice-cold PBS to remove debris and non-adherent vibrios, homogenized 
in 2 mls PBS and serial dilutions plated onto agar plates containing Sm. (Previous testing had 
shown that recoveries from Sm-plates were comparable to those obtained using 
thiosulfate/citrate/bile/sucrose plates). Representative colonies were examined for 
agglutination using monoclonal antibodies directed against the relevant LPS. The limit of 
detection was 20 CFU; negative samples were given a value of 10 CFU for statistical analysis. 
 
d) Competition studies 
 The colonization potentials of wild-type and tcpA::Km-mutant bacteria were directly 
compared in competition experiments as described previously (13). BALB/c and CD1 mice of 
various ages were infected with a mixed suspension of the two strains, the input ratio being 
determined retrospectively by spreading the inoculum on plates containing Sm or both Sm 
and Km. After 24 hours the SIs were excised and homogenised and the resulting suspensions 
again plated on both media for determination of output ratios.  
 
Sample collection 
Blood samples were collected by tail bleeding and the resulting sera stored at -20°C. Two 
procedures were used to gather samples for estimation of intestinal IgA responses following 
immunization. Supernatants were prepared from homogenates of fresh FPs (24) and in some 
experiments additional animals were immunized and sacrificed to allow for preparation of 
tissue extracts using the perfusion-extraction technique (PERFEXT) (178).  
 
For preparation of FP supernatants, seven fresh FPs were collected into Eppendorf tubes 
containing 600 µl of ice-cold PBS buffer with 0.1 mg of soybean trypsin inhibitor (STI; 
Sigma) per ml, 1% (wt/vol) bovine serum albumin (BSA), 25 mM EDTA, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 50% (v/v) glycerol (24). The pellets were 
emulsified and left at 4°C for 4 h. Debris was removed by centrifugation (15.5k x g, 4°C) and 
the resulting supernatants stored at -20°C. FPs were collected and supernatants stored in tubes 
which had been pre-blocked with 1% BSA-PBS overnight at 4°C. When analyzing the 
antibody content in the FP supernatants the samples were always kept on ice. 
 
Mucosal tissue extracts were prepared using a modified version of the PERFEXT method 
(178). Briefly, animals were anaesthetized and perfused with at least 20 ml 0.1% heparin-PBS 
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per mouse before removal of the lung, small intestine, caecum and large intestine. Tissue 
samples were then stored at –20°C in 450 µl PBS solution containing 2 mM PMSF, 0.1 
mg/ml of STI, and 0.05 mM EDTA. The tissue samples were later thawed and permeabilized 
by addition of saponin (Sigma) to a final concentration of 10% (vol./vol). After incubation at 
4°C overnight, SNs were collected by centrifugation at (15.5k x g, 10 min) and frozen at -
20°C. 
 
Analysis of antibody responses 
a) Enzyme-linked immunosorbent assay (ELISA) 
Antibody responses to LPS, CTB and membrane proteins (MP) were analyzed as described 
before using ELISA (75). Briefly, high-binding plates (Greiner, Germany) were sensitized 
with (O1 or O139) LPS or (O1) MP (all 5 µg/ml in PBS) overnight at 4°C. Low-binding 
plates (Nunc, Denmark) were similarly sensitized with GM1 ganglioside (0.3 nmol/ml in 
PBS) 
 
and then further incubated with CTB (0.5 µg /ml). Following blocking with 1% BSA-
PBS test-samples and a positive control of known activity were titrated in three-fold falling 
dilution and incubated for 4 hours at 37°C. The following conjugates were used according to 
the manufacturers description: goat-anti-mouse IgA conjugated to horseradish peroxidase 
(HRP) and goat-anti-mouse IgG-HRP (Both from Southern Biotech) or goat-anti-mouse IgG-
HRP (Jackson ImmunoResearch Europe Ltd). 
Because of variations in the immunoglobulin content of the tissue and FPs, IgA ELISA titres 
were standardized per mg of total IgA as described previously (179), with the following 
modifications: High Binding ELISA trays were sensitized with goat anti-mouse IgA (1 µg/ml, 
Southern Biotech) in PBS; samples and standard (purified mouse IgA, Southern Biotech) 
were titrated in three-fold falling dilutions; and goat-anti-IgA-HRP conjugate was used as 
above. 
 
b) Bactericidal assay 
Serum samples of specific interest were also tested for the presence of (complement-
dependent) bactericidal antibodies in a microtitre plate assay, described elsewhere (12). 
Briefly, V. cholerae O1 or O139 strain H1 and AI-1838 respectively was cultured to early-
log-phase in LB medium and spread (ca. 104 CFU) onto LB-agar plates containing 
streptomycin (Sm; 200 µg/ml). After incubation for 18 h at 37°C, the resulting growth was 
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harvested with PBS. The OD600 was used to guide dilution of the suspension to a final 
concentration of ca. 2 x 105 vibrios per ml in PBS, containing Sm (200 µg/ml) and 20 % 
guinea pig serum as the source of complement. This suspension was then added to a microtitre 
tray (50 µl/well) containing equal volumes of samples (or a standard of known activity) 
previously serially titrated in PBS, resulting in a final bacterial concentration of 105 per ml 
and a final complement concentration of 10%. Negative control wells (negative for bacterial 
growth) received the same solution without bacteria. After incubation for 70 min at 37°C, 100 
µl pre-warmed 4x LB medium (containing Sm) was added to each well. Incubation was 
continued for approximately 5 h at 37°C, until the positive control wells (bacterial suspension 
added to PBS with no antibody) reached OD600
 
 ca. 0.35 (Labsystems Multiskan MS 
spectrophotometer). The mean ODs of negative and positive control wells (a and b, 
respectively) were used to calculate an OD that represented a 70% inhibition of bacterial 
growth (OD = a + 0.3[b − a]). This value was then used to assign a lytic endpoint to each test 
sample, this being the highest dilution causing ≥70% killing.  
Statistical analyses 
The Prism software system GraphPad 4.03 (GraphPad Software Inc., San Diego, CA, USA) 
was used for all statistical analyses. Multigroup comparisons were performed using either 
one-way or two-way-(repeated measurement)-ANOVA with Bonferroni’s post-test if not 
noted otherwise. The protection factor (PF) was calculated by dividing the geometric mean 
excretion of the control group with the excretion observed in the sample of interest at the 
same time-point. The relationship between corresponding antibody estimates or between 
different antibody estimates and colonization (or PF) was evaluated using a Pearson 
correlation test. Two-sided P-values < 0.05 were considered as significant and asterisks or 
crosses denote probability values (* P < 0.05, ** or ++ P < 0.01, *** or ++ P < 0.001). 
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Results and comments 
 
Induction of strong immunity to viable and killed V. cholerae 
following systemic or mucosal vaccination of conventional adult mice 
(Paper I) 
 
Viable V. cholerae O139 administered via the IN, PO or IP route is immunogenic 
The inability of pathogenic V. cholerae to colonize the conventional adult mouse gut has 
made it difficult to elicit consistently strong antibacterial immunity (24). Recent reports have 
however shown that attenuated live V. cholerae O1 El Tor vaccines administered by the 
intranasal IN route as four doses over a period of 56 days induce strong serum antibacterial 
immunity (29, 154). Therefore initial experiments were performed in our laboratory with 
viable V. cholerae O1 or O139 administered IN on days 0 and 28. These experiments 
convincingly showed that our simplified dosing regime induced not only strong serum 
antibacterial immunity but also intestinal antibodies to LPS. In the context of enteric defence 
it was of interest to extend this observation to a comparison of intestinal responses following 
IN immunization or PO immunization. Adult BALB/c mice were therefore immunized IN or 
PO on days 0 and 28 with ca. 109 viable V. cholerae O139. In parallel, mice were also 
vaccinated IP with ca. 107
 
 O139 bacteria. Analysis of the serum anti-O139 LPS response 
using ELISA revealed that IP and IN immunization effectively induced serum antibody 
responses with similar kinetics and high IgG1:IgG2a subclass ratios, that in strength were 
significantly greater than those induced by the PO route. Later studies revealed that higher 
immunizing doses are required to elicit comparable serum anti-LPS responses by the oral 
route. 
In addition to analyzing serum antibody responses following vaccination, two sampling 
techniques were compared for deriving samples suitable for estimation of gut IgA responses 
using ELISA.  Supernatants were prepared either from intestinal tissue extracts - prepared 
using a modified version of the perfusion-extraction technique (PERFEXT) (178)  - or from 
homogenates of fresh FPs (24). The latter method is far more convenient and is widely used, 
but in the mouse the hepato-biliary transport of IgA from serum via bile to the gut means that 
FP IgA titres might not accurately reflect local antibody synthesis in the intestine (43). We 
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found that, for a given immunization route, the strength of the intestinal anti-LPS IgA 
antibody response monitored using tissue extracts was comparable to that detected in 
corresponding FP samples. Importantly, these indices of anti-LPS immunity were found to 
correlate significantly (r  ≥ 0.85 and P < 0.0001 for small intestinal, caecum and large 
intestinal vs. FP samples).  The disproportionately low content of IgG, and high content of 
IgA, antibodies to LPS in the PERFEXT extracts, relative to the corresponding serum levels, 
precludes the possibility of significant transudation of serum antibody into the gut. 
Collectively our data provide an important validation of the use of FP supernatants as a 
convenient guide to local IgA antibody production. Consistently the PERFEXT and FP-
samples also showed that the PO and IN routes generated similarly strong intestinal IgA 
responses. Intestinal responses generated by IN immunization however, tended to be more 
consistent than those following PO vaccination. In contrast to the mucosal routes, IP 
immunization did not generate any significant IgA responses.  
 
Formalin-killed V. cholerae is immunogenic in adult mice 
Ongoing research into inactivated cholera vaccines made it of interest to evaluate the mucosal 
immunogenicity of inactivated V. cholerae O139. Two experiments were therefore performed 
with fk whole cell vaccines administered either IN or PO using ca. 5 x 108 and 5 x 109
 
 
bacteria per dose respectively. In each experiment two groups were immunized on days 0 and 
28 with viable or fk V. cholerae O139 strain AI-1838. A third group was also immunized 
more intensively, receiving six doses of fk AI-1838 on days 0, 1, 2, 28, 29 and 30. For both 
the IN and PO route, six doses of killed bacteria were similarly immunogenic to two doses of 
viable bacteria. Mice in these groups mounted significantly stronger serum IgG and intestinal 
IgA anti-LPS ELISA responses than animals given only two doses of inactivated bacteria. 
Importantly the mice immunized with six doses of killed bacteria mounted more consistent 
serum and intestinal antibody responses than those receiving only two doses.  
V. cholerae O1 and O139 display similar mucosal immunogenicity 
Because of our interest in bivalent O1 and O139 vaccines we also wished to investigate the 
relative immunogenicity of these two serogroups. Viable V. cholerae O1 or O139 were 
therefore administered IN or PO, using the same dosing protocols as in the previous 
experiment. Two weeks after the secondary immunization on day 28 these mice were sampled 
for serum and FPs. Mice were also sacrificed for collection of PERFEXT whole small 
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intestinal samples. The standardized IgA responses detected in these samples are expressed as 
fold-rises above the GM O1 or O139 titre of 8 control samples prepared from unimmunized 
animals. 
 
V. cholerae O1 and O139 elicited very similar levels of intestinal IgA antibodies following IN 
or PO immunization, whether estimated using FPs (Fig. 2) or PERFEXT extracts. Irrespective 
of the serogroup we observed significant correlations between the standardized anti-LPS IgA 
titres detected using the two sampling techniques (r = 0.89 and P < 0.0001 for O1; r = 0.84 
and P = 0.0002 for O139). The serum IgG responses were also very similar regardless of the 
immunization route or strain.  
 
 
Wild type V. cholerae O139, as well as the attenuated live O139 vaccine CVD112, has been 
shown in volunteers to have strong protective efficacy (≥80%) against challenge (108, 165). 
Conflicting data have however been published regarding the capacity of V. cholerae bacteria 
of the O139 serogroup to induce significant serum bactericidal responses (36, 108, 125, 165). 
These responses, which measures the ability of serum antibodies to serogroup specifically kill 
V. cholerae in the presence of complement, and which successfully have been used to guide 
the development of the presently licensed oral O1 cholera vaccines (67, 92), was therefore 
recently further studied by Attridge et al. (12, 14). Although in these studies the conflicting 
Fig..2. Intestinal IgA antibody 
responses in BALB/c mice 
immunized with viable V. cholerae 
O1 or O139. Four groups of mice 
were inoculated with the O1 strain 
H1 (closed bars) or the O139 strain 
AI-1838 (open bars) on days 0 and 
28, using doses of 5 x 108 CFUs IN 
(n = 8 / group) or 5 x 109 CFUs PO 
(n = 7 / group). Since background 
titres differ in the O1 and O139 
ELISA systems, standardized FP IgA 
anti-LPS ELISA responses detected 
on day 42 are expressed as (GM + 
SD, log10) fold-rise in antibody titre, 
in relation to the GM pre-
immunization control titres. 
Statistics: P > 0.05 for all 
comparisons between the O1 and 
O139 groups. 
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results observed for the O139 bactericidal responses were indicated to reflect variations in the 
assays used to determine the bactericidal titres, the relevance of these estimates in evaluation 
of the immunogenicity elicited by V. cholerae O139 has recently been questioned (137). This 
study shows that the immunogenicity of O1 and O139 vaccines can be compared in the new 
adult mouse model, and indicates that the two serogroups are similarly immunogenic. Further 
studies comparing both the immunogenicity and protective capacity of O1 and O139 vaccines 
administered via different routes has therefore been initiated. 
 
 
Establishment of intestinal V. cholerae colonization in conventional 
adult mice (Paper II) 
 
Streptomycin treatment makes adult mice receptive to colonization by both V. 
cholerae O1 and O139 
It has been known for a long time that germfree adult mice can be consistently colonized with 
pathogenic V. cholerae following oral infection (136), and  that the normal gut flora is a major 
impediment to successful gut colonization by V. cholerae in several animal species (131). 
These observations prompted us to examine the possibility of depleting the intestinal flora 
using oral Sm treatment to possibly make mice receptive to colonization by Sm-resistant V. 
cholerae bacteria. Initial studies revealed that mice administered Sm-containing drinking 
water (5 mg/ml) before inoculation with viable V. cholerae excreted viable bacteria for 
significantly longer than untreated age-matched controls. Mice maintained on Sm post-
inoculation (0.2 mg/ml) were also found to excrete significantly higher numbers of viable V. 
cholerae for a longer period of time than those receiving Sm only prior to inoculation. 
Therefore a Sm-dosing protocol involving continuing exposure to antibiotic, beginning 24 
hours prior to administration of V. cholerae, was adopted for further use.  
 
In the following study we could also show that oral inoculation with 109 bacteria was 
uniformly well-tolerated and that there was no significant difference in the colonization 
profiles between the V. cholerae wild-type O1 (El Tor strain H1) or O139 (MO10) bacteria. 
These observations were confirmed in two later repeat experiments, and V. cholerae O139 
strain AI-1838 also resulted in similar patterns of colonization. Our observations are in 
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agreement with human volunteer studies showing that O1 El Tor and O139 cholera has 
similar clinical characteristics (108). 
 
V. cholerae colonize the intestine following infection of streptomycin treated mice 
Cholera is mainly a disease of the small intestine. V. cholerae bacteria can however be 
recovered from all regions of the intestine of infected patients. Therefore we examined the 
localization of V. cholerae O139 in the gut of Sm-treated adult mice. At various time points 
following infection with 109
 
 bacteria we sacrificed mice and enumerated bacterial persistence 
in the small intestine (SI), caecum (C) and large intestine (LI). Bacterial recoveries from 
carefully washed intestinal tissue samples were found to correlate significantly with the levels 
of bacteria excreted in FPs (P<0.0001 for all comparisons and r = 0.79 for SI, 0.90 for C and 
0.91 for LI vs. FP). Although much greater numbers of epithelium-associated bacteria were 
consistently recovered from the large bowel compared with the SI, indicating a limitation of 
the model, the highly significant relationship between gut colonization and bacterial excretion 
shows that the latter provides a convenient way to monitor intestinal V. cholerae infection. 
Experiments with lower inocula importantly showed that the bacteria clearly replicates within 
the gastro-intestinal tract of Sm-treated mice. Recoveries of challenge organisms in different 
gut tissues or in fresh FPs were consistently greater than the initial challenge inoculum for 
periods of 4 or 8 days respectively. 
Refined protocols for infection improve colonization 
Initial challenge studies showed that it was possible to protect adult mice against colonization 
by vaccination with either live or killed V. cholerae vaccines (Se below). However in these 
initial experiments we also observed variable excretion patterns among challenged naïve 
control mice, precluding comparison of protection beyond day 6 at best. Several different 
variables possibly effecting colonization were therefore examined. Initial experiments 
revealed, similarly to other gastro-intestinal infection models, that the mouse strain greatly 
affected the patterns of colonization. Whereas BALB/c, C57BL/6, and SJL mice gradually 
cleared the infection over a period of about two weeks, C3H/HeN mice continued to excrete 
significant numbers of vibrios for at least three weeks post-infection. Colonization data from 
two pooled experiments with BALB/c and C3H/HeN mice are shown in Figure 3A; 
exemplifying the two types of colonization patterns observed. Interestingly the serum IgG 
responses detected three weeks after inoculation did not correlate with these two patterns of 
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colonization (Fig. 3B), indicating that prolonged colonization is not required for development 
of antibacterial immunity in Sm-treated adult mice. The prolonged colonization seen in the 
C3H/HeN mice did however suggest that such hosts might provide a longer interval for 
demonstration of the protective effects of prior immunization. As shown in a later challenge 
study (Fig. 5) this was however not the case and so no further studies were performed with 
this strain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A series of experiments was therefore set up to compare various modified Sm dosing regimes 
and also the impact of adding saccharin to the Sm-containing drinking water as a sweetener to 
increase intake of antibiotic. Although saccharin had only a very marginal effect, we did 
observe a slight improvement in colonization among mice treated with Sm more intensely i.e. 
Fig. 3. Bacterial excretion and serum antibody responses in two mouse strains following oral 
infection with V. cholerae O139. Pooled results from two experiments with BALB/c (closed 
circles/bar, n = 13) and C3H/HeN (open circles/bar, n = 13) mice are shown. In panel A the 
mice received Sm-containing drinking water (5 mg/ml) for 24 hours before inoculation with 
ca. 109 viable Sm-resistant V. cholerae O139 strain MO10 on day 0. The mice also received 
Sm-water (0.2 mg/ml) after challenge. Faecal bacterial excretion was monitored and the 
CFUs are shown as (GM + SD) on a log10 scale. In panel B serum collected on day 21 post 
infection were analyzed for antibody responses to O139 LPS using ELISA. The IgG 
responses are expressed as fold-rise in antibody titre (GM + SD) on a log10 scale, in relation 
to the GM pre-immunization control titres. 
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involving a longer period (48 hours) of dosing pre-challenge and maintenance on a higher 
concentration (1 mg/ml) of Sm post-challenge. Applying this dosing strategy we finally tested 
whether a lower infectious dose might be sufficient to provide consistent colonization of 
unimmunized hosts. Counter-intuitively, we found that FP excretion was significantly 
prolonged following infection of 14-week old mice with 107 V. cholerae O139 as compared 
with the previously used challenge dose of 109 bacteria. Importantly the variability at each 
time point was much reduced, and also the level of excretion was maintained above 107 CFU 
even 8 days after infection. Later experiments using the refined dosing protocol confirmed 
these findings (Fig. 7D) and also showed that there was again no significant difference in the 
small intestinal colonization profiles between the O1 and O139 serogroup (Fig. 4). Why a 
100-fold lower challenge dose should result in more sustained and consistent colonization of 
naïve mice remains unexplained. However, it may be that a higher infectious dose induces 
stronger activation of the innate immune system of the gut, thereby which inhibiting V. 
cholerae persistence. Such responses have been described in patients with severe cholera (52, 
123). 
 
  
 
 
Fig. 4. Recoveries of V. cholerae 
O1 or O139 from the small 
intestine following oral infection 
of Sm-treated BALB/c mice. Two 
groups of BALB/c mice were 
treated with a more intensive Sm 
dosing regimen (5mg/ml Sm for 48 
hours prior to inoculation and 1 
mg/ml after challenge). The 
animals were inoculated with ca. 
107 V. cholerae O1 or O139 strain 
H1 and MO10 respectively. 
Epithelium-associated vibrios 
recovered from small intestines 
three days after inoculation were 
enumerated as described in 
Methods. Each point represents 
bacterial recovery from an 
individual mouse (log10 CFU). 
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Expression of CT and TCP are not required for colonization  
CT and TCP are critical virulence determinants which enable V. cholerae to establish 
infection and disease in the human intestine (65, 91, 167). To evaluate the significance of 
these factors in our modified model we assessed the colonization potential of mutant strains 
unable to express either factor. Similarly to volunteer studies with atoxigenic live cholera 
vaccines (65, 91), we found that CT was not required for persistent colonization. Our findings 
are also in agreement with colonization studies in infant mice (170), and with recent 
observations by Olivier et al. (116, 117) in Ketamine and Sm-treated, juvenile C57BL/6 mice.  
 
In a preliminary experiment comparing FP bacterial excretion profiles of mice infected with 
wild-type V. cholerae or isogenic mutants lacking functional TCP expression, we observed no 
significant dependence of this virulence factor for colonization. This was unexpected given 
earlier findings in the IMCM, which have shown dramatic attenuation and colonization 
impairment associated with mutations affecting TCP expression (13, 170). We therefore 
conducted mixed infection competition experiments, to compare the potential of a tcpA::Km 
mutant strain to colonize the small intestine in comparison with wild-type bacteria, in mice of 
different ages. Experiments in both adult outbred CD1 and inbred BALB/c mice showed that 
our preliminary studies were correct, and that colonization in mice of intermediate age were, 
at best, only marginally dependent on TCP. Similarly Olivier et al. also recently reported that 
TCP expression was not required for colonization of the juvenile mice in their system (116, 
117).  
 
In conclusion these results preclude any examination in the adult mouse V. cholerae challenge 
model of the role of the TCP pili in enhancement of the immunogenicity of inactivated 
cholera vaccines. The apparent disparity in dependence of TCP for colonization in infant mice 
as compared with colonization in older mice is however fascinating. Although it may reflect 
differences in the models used for establishing colonization or age-dependent changes in the 
intestinal epithelium, it could also be that the host intestinal milieu changes following 
acquisition of a commensal flora. Experiments in germ free mice of different ages comparing 
colonization of WT bacteria and mutants lacking TCP are therefore warranted. 
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Protection against colonization by live and killed V. cholerae O1 
and/or O139 vaccines (Papers II and III) 
 
Immunization with live or killed V. cholerae O139 protects against colonization  
(Paper II) 
Pre-clinical studies of the determinants of direct protection following infection or 
immunization with V. cholerae have previously been primarily performed in model systems 
that are fairly expensive and surgically demanding (131). In contrast, adult mice are very 
convenient, inexpensive experimental animals and the availability of inbred and congenic 
mutant strains facilitates evaluation of immunogenicity. Having established effective 
immunization protocols and also demonstrated that Sm-resistant V. cholerae can colonize the 
intestine of Sm-treated adult mice, it was of interest to investigate whether colonization would 
be curtailed in hosts which had been previously immunized using these protocols. Challenge 
experiments with 109
 
 V. cholerae (conducted prior to our later refinement of the Sm-dosing 
regime) were therefore set up, generally using the IN or PO routes of immunization. Since the 
IP route is commonly used in immunogenicity studies mice immunized in this way were also 
tested in a few experiments. Immunization on days 0 and 28 with live V. cholerae O139 
administered via either the IN, PO or IP route was found to elicit significant protective 
immunity, although no differences in the levels of excretion of challenge organisms were 
apparent until 4 days after challenge. At this time point the GM excretion was most reduced in 
the IN immunized mice - about 3900- fold as compared with the unimmunized controls. In 
contrast, excretion by mice immunized PO or IP was only reduced about 100- or 300-fold 
respectively. Subsequent PO immunization experiments were therefore performed with 
slightly higher immunizing doses.  
To ascertain whether the present model would be applicable to evaluation of inactivated 
vaccine candidates we inoculated mice PO with 5 x 109 fk V. cholerae O139 on days 0, 1, and 
2 for primary immunization and 28, 29 and 30 for secondary immunization. Mice in other 
groups were immunized PO as before, on days 0 and 28 with 5 x 109 live or fk V. cholerae. 
Two weeks after the last immunization these groups and age-matched naïve controls were 
challenged homologously with 109 vibrios. The results indicated that vaccine viability is 
important for induction of host protective immunity. Mice immunized with two doses of 
viable V. cholerae showed significantly faster clearance of the challenge organisms than 
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unvaccinated controls, or mice given two doses of fk bacteria. Importantly however, six doses 
of killed V. cholerae conferred immunity to challenge, indicating that the model could be 
applied to the testing of inactivated vaccine candidates. Similarly to the previous experiment 
there was a clear lag period of 4 days before expression of immunity in the group immunized 
with live bacteria. 
 
When the protective effect induced by PO vaccination with live V. cholerae O139 was 
evaluated in C3H/HeN mice we again observed this delayed onset of immunity. Further, we 
also observed that although the immunized animals excreted significantly fewer challenge 
organisms than the age-matched controls on days 4, 5 and 6 post-challenge, vaccination was 
not sufficient to confer sterilizing immunity in this strain (Fig. 5).  
 
 
 
Intranasal vaccination elicits serogroup-specific protection against colonization 
(Paper II) 
Having improved the challenge protocol as described above, we examined whether protective 
immunity was serogroup-specific in the new adult mouse model, as is inferred to be the case 
in man. Two groups of mice were immunized IN with 5 x 108 viable V. cholerae O1 or O139 
using a dosing schedule shown to generate comparable immune responses to the two 
Fig. 5. PO immunization with viable 
V. cholerae O139 confers immunity 
to homologous challenge. One 
group of C3H/HeN mice were 
immunized PO with V. cholerae 
O139 strain MO10 (closed circles, n 
= 6), as described in the legend to 
Figure 2. Another group of mice 
were left unimmunized (open 
circles, n = 8). Two weeks after the 
last immunization these mice were 
Sm-treated and orally challenged 
with ca 109 MO10 bacteria as 
described in the legend to Figure 3. 
FP excretion of challenge organisms 
was monitored and is shown as (GM 
± SD) log10 CFU. 
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serogroup antigens (Fig. 2). Following homologous or heterologous challenge with ca. 107
 
 V. 
cholerae O1 or O139 on day 42, bacterial excretion profiles were compared. The patterns of 
colonization within the two unimmunized control groups were found to be similar for both 
serogroups, confirming our previous observations (Fig. 4). Also we observed for both 
serogroups that vaccination did confer significant immunity to homologous challenge, 
whereas the patterns of colonization were not significantly altered by prior immunization with 
V. cholerae of heterologous serogroup. These differences were also apparent when comparing 
the GM day 17 protection factor (PF) for each group above the controls (Fig. 6). One animal 
out of six immunized with V. cholerae O139 and challenged heterologously with O1 bacteria 
was however partially protected, as indicated by the more variable PF in this group. 
 
 
 
 
It is fascinating that even after lowering the challenge inoculum 100-fold, host immunity was 
clearly still delayed, and surprisingly even more so than in our earlier experiments using the 
higher challenge dose (Fig. 5). Nevertheless this experiment, which was also later confirmed, 
showed that the fortuitous improvement in the duration and reproducibility of colonization 
observed using the lower challenge dose made the model more robust and provided a longer 
window for expression of protective immunity.  
 
 
Fig. 6. IN immunization with viable 
V. cholerae confers immunity to 
homologous re-challenge. Two 
groups of twelve BALB/c mice were 
immunized IN with V. cholerae O1 
strain H1 or O139 strain AI-1838, as 
described in the legend to Figure 2. 
One extra group of 12 age-matched 
controls was left unimmunized. Sm-
treatment was commenced on day 40 
and on day 42 each group was sub-
divided for oral challenge with ca. 
107 H1 or MO10. FP excretion of 
challenge organisms was monitored 
and used to calculate the day 17 PF 
(log10 GM + SD), as described in 
Methods. 
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Co-administration of CT enhances homologous and heterologous protection following 
oral immunization with live or formalin-killed V. cholerae O139 (Paper III) 
 In our earlier studies in this model we could show that mucosal vaccination conferred 
immunity to homologous challenge with V. cholerae (See Figure 5 and 6), although 
expression of significant immunity was delayed; especially so in the previous IN 
immunization experiment using a challenge dose of 107 bacteria. It was therefore of great 
interest to ascertain whether the strength of the host anti-bacterial immune response could be 
improved, either by inclusion of extra immunizing doses, and/or, in the present context, by the 
addition of exogenous CT as adjuvant at the time of vaccination. In addition, we wanted to 
compress the immunization/challenge protocol to make the model more convenient to use. 
Since the oral route of immunization is the route of choice for both live attenuated and killed 
cholera vaccines, we initially immunized mice either IN or PO on days 0 and 14 with live  
V. cholerae O139. Additional unimmunized age-matched mice were set aside as controls. 
When examining host antibacterial responses ten days after the last immunization (day 24) we 
found that both routes elicited strong serum bactericidal responses and intestinal IgA titres to 
Fig. 7. Antibacterial immune responses and protection following mucosal immunization using a 
compressed schedule. Two groups of fourteen mice were inoculated with viable V. cholerae strain 
AI-1838 on day 0 and 14, using doses of 5 x 108 CFUs IN (closed bars or ●) or 5 x 10 9 CFUs PO 
(open bars or  ○). Yet another group of twelve age matched controls were left untreated (striped 
bars or ▲). Specimens fo r estimation of antibody responses to V. cholera O139 responses were 
collected on day 24. Serum was analyzed for both bactericidal (panel A) and anti-LPS IgG ELISA 
(panel B) antibodies. The standardized anti-LPS IgA responses in extracts from fresh FP (panel C) 
were also measured using ELISA. On day 26 half of the animals in each group were also 
challenged with V. cholerae O139 strain MO10 as described in Methods (panel D), doses being ca. 
107 bacteria per mouse. Results are expressed as log10 (GM ± SD). 
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O139-LPS, although the serum IgG response was significant only in the IN immunized group 
(Fig. 7A-C). Further, we also challenged the immunized groups and the naive controls on day 
26 with ca. 107
 
 V. cholerae O139 strain MO10. When analyzing the patterns of colonization 
following challenge we found that both of the immunized groups on several occasions excrete 
significantly fewer challenge organisms than the unimmunized control group (Fig. 7D). These 
results were encouraging with regards to compressing the model, yet fully sterilizing 
immunity was again delayed; especially so in the PO group. Further, no reduction in the initial 
colonization was observed for any of the immunized mice, prompting experiments with more 
intensive dosing protocols.  
When such protocols were applied in a preliminary experiment we observed that repeated PO 
inoculations with 5 x 108
 
 bacteria were well tolerated, while higher doses were not. Hence in 
the following experiment we adopted a protocol involving orally immunization on days 0 and 
2 for primary immunization and on days 14 and 16 for secondary immunization, followed by 
challenge on day 26.  
Our interest in the development of bivalent O1/O139 V. cholerae vaccines (67) prompted a 
study to evaluate the immunogenicity and protective potential of bivalent O1/O139 
immunization in conventional adult BALB/c mice. Animals were orally immunized as 
described above, with each dose comprising ca. 5 x 108 V. cholerae (H1 and AI-1838 bacteria 
in a 1:1 mixture). A second group of mice received the same bacterial suspensions 
supplemented with CT (7.5 μg/dose). Ten days after the last dose the immunized groups and a 
group of age-matched naive controls were orally challenged with ca. 107
 
 V. cholerae O139 
strain MO10.  
A comparison of the bacterial excretion patterns following challenge showed that V. cholerae 
O139 colonization was reduced in vaccinated hosts. Interestingly the switch to four 
immunizing doses did not appear to enhance the anti-bacterial impact of immunization with 
viable bacteria, since these hosts excreted only marginally less challenge organisms that the 
controls during the early post-challenge period and expression of immunity was still 
considerably delayed. Strikingly however, the extent of protection in the CT-adjuvanted group 
was significantly better than in the non-adjuvanted group at most time-points. Not only was 
the duration of  colonization greatly reduced in this group, but FP excretion of challenge 
bacteria on day 2 post-challenge was also ca. 130-fold lower than in the control group. These 
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observations were not paralleled by differential anti-LPS responses in the two vaccinated 
groups however. Whether assessed using tissue extracts or FP supernatants, the (standardized) 
anti-O139 LPS IgA titres revealed highly significant intestinal antibody responses which were 
not affected by co-administration of CT. Yet these IgA responses were found to correlate 
inversely with colonization as early as 2 days after challenge (r = - 0.50 and P = 0.0406), and 
with even stronger significance from day 8 (r = -0.85, P < 0.0001) and onwards. 
  
 
Co-administration of CT enhances anti-bacterial immunity following oral 
immunization with fk V. cholerae O139 (Paper III) 
Encouraged by the observations in the previous study we wished to examine if oral 
immunization with inactivated whole cell cholera vaccine could similarly induce protective 
immunity, and if so to determine the potential adjuvant effect of co-administered CT. We 
therefore inoculated mice PO with fk V. cholerae O139 with and without CT (7.5 µg/dose) on 
days 0, 1, and 2 for primary immunization and 14, 15 and 16 for secondary immunization. 
Extra mice were similarly treated with CT alone or left unimmunized. Six weeks after the last 
immunization these groups were Sm-treated and two days later challenged with ca. 107 V. 
cholerae O139; additional animals were also challenged 10 days after immunization as in the 
previous experiment. When analyzing bacterial excretion following challenge we observed 
that immunization with CT alone did not induce protection against V. cholerae colonization 
(shown for the O139 challenge in Figure 8). These observations indicate that neither adaptive 
nor innate immune mechanisms induced by CT alone are protective in the adult mouse model.  
 
In contrast, and regardless of the interval between vaccination and challenge, mice immunized 
with fk V. cholerae O139 displayed immunity to homologous challenge. The protective 
potential was most pronounced with the longer interval (challenge on day 60, Fig. 9), 
suggesting a maturation of the protective potential of host antibacterial immune responses. In 
neither case did CT significantly enhance the anti-bacterial immunity elicited by fk bacteria. 
Nevertheless the greatest impact on colonization was observed in the CT-adjuvanted group, 
with a 270-fold lower excretion of the challenge organism two days after challenge, compared 
with only 15 -fold reduction in the group not receiving CT (Fig. 9). 
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Fig. 8. Immunization with CT does not induce protection. BALB/c mice were inoculated PO on 
days 0, 1, 2, 14, 15 and 16 with CT (7.5 µg/dose) or left unimmunized. On days 60 these groups 
were challenged with V. cholerae O139 strain MO10  as described in Methods, doses were ca. 107 
bacteria per mouse (n ≥ 6 per group). Fecal excretion of challenge organisms was monitored and is 
shown as (GM + SD) log10 CFU. 
Fig. 9. Co-administration of CT improves protection of fk V. cholerae O139. BALB/c mice were 
immunized PO on days 0, 1, 2, 14, 15 and 16. One group of animals were immunized with 5 x 108 
fk V. cholerae O139 strain AI-1838 (closed bars, n = 34). A second group were also administered 
CT (7.5 µg/dosing) together with the fk bacteria (open bars, n = 32). A third group of age-matched 
controls were left untreated (striped bars, n = 26). On day 60 these groups were challenged either 
homologously with V. cholerae O139 strain MO10 or heterologously with V. cholerae O1 strain 
H1 as described in the legend to Figure 8 (n ≥ 6 per group and time point). Colonization on days 2 
and 9 post-challenge is shown as (GM + SD) log10 CFU. 
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Because V. cholerae O1 El Tor and O139 bacteria share several surface antigens (38, 181) we 
also examined whether PO immunization with fk V. cholerae O139 could induce serogroup 
cross-protection. Subsets of the animals immunized as described above were therefore 
challenged heterologously on days 26 and 60 with V. cholerae O1 El Tor strain H1. The O1 
colonization patterns showed that mice immunized with fk V. cholerae O139 were 
significantly protected against colonization only when challenged on day 60 (Fig. 9). This 
result contradicts our earlier conclusion that protection in this model is serogroup-restricted. 
However these earlier results (see Figure 6) emanated from studies using a 14-day interval 
between IN vaccination and challenge, which now appears sub-optimal. Possibly the buildup 
of strong immunity prior to challenge at day 60 allowed detection of weaker but significant 
cross-reactive immunity not detected in our earlier experiments. Interestingly the importance 
of the immunization/challenge protocol appears to be minimized by adjuvanting with CT, 
since mice immunized with both bacteria and CT excreted significantly fewer challenge 
organisms than controls whether challenge occurred early or late after vaccination. The GM 
day 9 PFs of animals challenged heterologously on day 60 was however only about 2500, 
compared with PFs ca.100,000 following homologous challenge.  
 
 
CT enhances mucosal antibody responses to LPS and also to non-LPS antigens shared 
between the O1 and O139 serogroups (Paper III) 
In a search for possible correlates of the homologous and heterologous protection data 
described in Figure 9, serum and FP samples collected just prior to challenge (days 24 or 58) 
were analyzed for antibody responses to various V. cholerae antigens. Both groups 
immunized with fk bacteria (± CT) displayed high levels of both serum IgG and intestinal IgA 
antibodies to LPS. Only the latter response was significantly increased by co-administration 
of CT with the fk bacteria. Consistent with our previous findings using the intranasal route of 
immunization (Fig. 6), anti-O139 LPS titres correlated significantly with protection (P < 
0.0001 and r ≥ 0.81 for both IgG and IgA vs. PF).  
 
The divergent effects of CT on intestinal IgA responses to live and killed V. cholerae  may be 
explained by the fact that viable bacteria represent a more powerful tool for eliciting an 
immune response than killed whole cell formulations (115). Hence the use of the former may 
have maximised the immune response, obscuring any effect of CT in these experiments. 
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Alternatively, since it has been known that CT has to be co-administered or at least given 
within a few hours before or after antigen administration to have adjuvant activity (100), it 
could be that after inoculation with live bacteria, much of the antigen stimulation of the gut 
immune system takes place after the period when CT is effective as an adjuvant. 
 
Pre-challenge serum samples collected from mice immunized as described in the legend to 
Figure 9 had no anti-O1 LPS antibody titres above the background levels of unimmunized 
controls (data not shown). The sera from day 58 were therefore tested for antibodies to 
membrane preparation (MP) from the O1 El Tor strain JBK70. By ELISA the two groups 
immunized with fk bacteria (±CT), but not those given CT only, displayed significant serum 
IgG titres to MP. Like the serum anti-LPS responses, this response was not increased by CT 
adjuvantation. Interestingly the serum IgG anti-MP titres correlated inversely with the level of 
colonization observed on day 9 post challenge with V. cholerae O1 in Figure 9 (P = 0.0007 
and r = - 0.63), suggesting that immunity directed towards non-LPS, serogroup-shared 
determinants might contribute to protection against colonization in this model.  
 
The cross-reactive antibody response was therefore analyzed further using immunoblotting of 
immune sera against a SDS-PAGE-separated crude whole cell lysate prepared from V. 
cholerae O1 El Tor strain H1. Previous immunoblotting experiments had shown that sera 
collected on day 24 generally react more strongly to the MP than sera from day 58, hence 
only the former sera were tested against the H1-lysate. Sera collected from mice given fk V. 
cholerae O139 (±CT) were found to react with several protein bands not detected by sera 
from unimmunized or CT-immunized mice (Fig. 10). Strikingly, the sera reacted most 
strongly with 18-19 kDa proteins (position c in Figure 10), with the serum from the CT-
adjuvanted group giving the strongest reaction. Monoclonal antibodies to TcpA did not react 
with these preparations, while mannose-sensitive hemagglutinin (MSHA) pilus specific 
antibodies stained bacterial proteins at ca. 17 kDa (position d in Figure 10), also apparently 
stained by sera from the CT-adjuvanted group. 
 
The best characterized protective antigens of V. cholerae are LPS and CT, although several 
studies suggest that immunity might also involve antibody responses to TCP and several other 
membrane proteins (62, 101, 146-148). Our finding that the anti-membrane antibody response 
correlated significantly with cross-serogroup protection would be consistent with this. 
Similarly, protection was also significantly improved by co-administration of CT together 
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with live V. cholerae, even in the absence of increased intestinal antibody responses to LPS. 
Taken together our immunization experiments suggest that both LPS and non-LPS antigens 
may be targets for protective host responses in the new model.  
 
 
 
 
 
 
Fig. 10. CT potentiates non-LPS cross-serogroup reactive antibody responses. Serum samples 
collected from mice immunized in Figure 9 with fk O139, CT and fk O139 or with CT alone were 
pooled, diluted 200-fold and immunoblotted against immobilized sonicated V. cholerae O1 strain 
H1 cultured in LB-medium over night, as described in Methods. Serum from unimmunized age-
matched controls (C) and a standard (Std) with known size was also included. Bands reacting more 
strongly in the CT + fk group were detected at estimated 30 kDa (position a), 27 kDa (b), 18-19 
kDa (c), 17 kDa (d) and 14 kDa (e).  
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Discussion and conclusions  
The main objective of this work has been to examine the feasibility of establishing a model 
for direct evaluation of the immunogenicity and protective efficacy of cholera vaccine 
candidates in conventional adult mice. Until now, the inability of pathogenic V. cholerae to 
colonize the conventional adult mouse gut has made it not only difficult to consistently induce 
strong antibacterial antibody responses, but also impossible to evaluate the impact of 
vaccination on protection against colonization in such hosts.  
 
The work described in this thesis thus started by delineating the immune response to viable  
V. cholerae administered mucosally or systemically. A simplified two-dose IN immunization 
schedule with viable V. cholerae was shown to be sufficient to induce strong serum anti-LPS 
responses comparable to those reported by others using a more demanding dosing regime (29, 
154). Significantly, these serum responses were accompanied by the induction of consistent 
intestinal IgA responses, which to our knowledge have not been previously reported following 
IN vaccination. Using slightly higher doses of viable bacteria we could also generate 
consistent gut and serum anti-LPS responses by the oral route. V. cholerae O1 and O139 
strains were similarly immunogenic when administered IN or PO. Comparable serum and 
intestinal anti-LPS responses could also be generated by mucosal (PO or IN) application of 
formalin-killed bacteria, although more intensive immunization regimes were then required 
for consistently strong responses. In contrast to most previous reports, these mucosal 
immunization schedules do not require co-administration of CT (although later studies 
revealed the adjuvant potential of this toxin) or any other adjuvant. Further, our immunization 
schedules also do not require pre-treatment with antibiotics or the use of germ-free animals 
(24, 37) for induction of significant immune responses.  
 
Our initial work also compared gut IgA responses estimated using two sampling techniques, 
involving the collection of fresh FPs or the preparation of intestinal tissue extracts. The 
observed significant correlation between these estimates validates the more convenient 
approach of measuring intestinal IgA responses using faecal pellet extracts, which offers the 
added benefit of allowing repeated sampling from the same animals. Our comparison of these 
two sampling techniques has been restricted to measurement of anti-LPS responses following 
administration of V. cholerae. It is feasible that this conclusion would not apply to antibody 
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responses to other antigens or organisms, yet preliminary results from a study with OVA as an 
antigen (U. Yrlid et al., unpublished) are in agreement with our findings. 
 
In parallel to our immunization studies, we have also undertaken the more demanding task of 
establishing a model for intestinal V. cholerae colonization using conventional adult mice. 
Initial experiments showed that pre-treatment of adult mice with oral Sm allowed intestinal 
colonization by V. cholerae strains of either O1 or O139 serogroup. Following Sm treatment 
and infection, viable V. cholerae were recovered from all regions of the gut, but in lower 
numbers from the small intestine compared with the caecum and large intestine. Importantly 
the intestinal bacterial loads in all regions of the gut were found to correlate significantly with 
bacterial excretion in fresh FPs, which thus provide a convenient indicator of the extent and 
duration of gut colonization. 
 
Later experiments surprisingly showed that mutant strains unable to produce TCP persisted in 
the intestine at levels no different to those of the WT organism. This is an apparent 
inconsistency with the human infection (65, 167) and represents a limitation of the model with 
regard to its usefulness in evaluating the protective capacity of novel cholera vaccines 
expressing TCP. Our work also revealed that atoxigenic V. cholerae colonized mice as 
efficiently as WT organisms. This observation was however not unexpected considering that 
CT production is not required for colonization of the infant mouse or human intestine (91, 
170). Also the absence of signs of diarrhea in our model is in agreement with several other 
studies in mice (24, 116, 136) and probably reflects the enormous capacity of the mouse colon 
to reabsorb fluids rather than a lack of in vivo CT expression, since we did observe significant 
anti-CTB responses following colonization. Further our aim was not to develop a new model 
for induction of fluid secretion and diarrhea since such models already exists (131, 135, 157, 
171), but instead a small animal model for evaluating antibacterial protection against 
colonization. 
 
When combining the protocols for immunization and colonization (the two ‘phases’ of the  
V. cholerae challenge model) we found that mice vaccinated mucosally or systemically with 
V. cholerae were comparatively refractory to V. cholerae colonization following challenge 
with the immunizing strain. Our challenge experiments indicate that vaccine viability is 
important for induction of host protective immunity, since six but not two doses of a killed 
whole cell vaccine induced similar rates of clearance of the challenge organisms as did two 
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doses of viable V. cholerae. Combining a lower inoculum of 107
 
 vibrios with a more intensive 
Sm-dosing regime allowed more consistent and sustained colonization to be established, 
facilitating detection of protective host immunity. 
Despite the strong intestinal antibody responses detected in intranasally immunized mice it is 
not the authors recommendation that this route should be adopted for human use with cholera 
vaccines, as has recently been suggested (118). The IN route is however suitable for initial 
immunogenicity studies of experimental cholera vaccines, especially when access to antigen 
is a limiting factor. A recent study has further shown that IN immunization of female mice 
with outer membrane vesicles from V. cholerae induces high serum IgA antibody responses 
which are sufficient for passive protection of suckling mice challenged orally with WT  
V. cholerae (144). 
 
In our final study we expanded our investigations of the oral route of immunization, which is 
the route of choice for both live attenuated and killed human cholera vaccines (96). Using a 
compressed and more intensive dosing protocol for oral vaccination we could show that co-
administration of CT as an adjuvant potentiates both protection and intestinal antibody 
responses to LPS and several other bacterial surface proteins/antigens. Importantly, non-LPS 
responses elicited by a killed whole cell V. cholerae O139 vaccine were also shown to 
correlate with the potential to protect against heterologous V. cholerae infection. Further 
evaluation of the experimental and clinical significance of antibody responses to surface 
proteins are warranted since such responses may be targets in maximally protective whole cell 
cholera vaccines.  
 
During the course of these studies Olivier et al. (116, 117) described a similar model for  
V. cholerae colonization of Sm-treated juvenile mice. Differences in methods used for 
establishing colonization, the age and strain of the host, and of the bacterial challenge strains 
make it difficult to compare the two systems. Yet it is apparent that their system, in contrast to 
our challenge model, is optimized for lethality, with an inoculum of only 108 bacteria 
representing a LD100 (116). This finding also contradicts many reports of investigators 
feeding tremendous numbers of pathogenic vibrios to adult mice without any adverse effects, 
and germ-free mice remain healthy following mono-contamination with toxigenic V. cholerae 
(24, 136). From an ethical point of view our model is therefore more acceptable, causing no 
deaths and only very marginal stress. Although Olivier et al. could show protection against 
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fatal WT V. cholerae infections in mice vaccinated with a multi-toxin deficient live cholera 
vaccine (116), no data showing protection against colonization was described. 
 
The work in this thesis is to our knowledge the first description of a model in conventional 
adult mice that allows protection against V. cholerae colonization to be evaluated directly. 
Taken together the new adult mouse V. cholerae challenge model is useful for studies of 
specific intestinal-mucosal and serum antibody responses as well as anti-colonization 
protective immunity after immunization with either live or killed cholera vaccines. The 
described V. cholerae challenge model thus promises to be a useful tool in the preclinical 
evaluation of novel oral cholera vaccines, and also likely in studies of the capacity of already 
existing vaccines to protect against new variants of epidemic V. cholerae strains. 
- 51 - 
Acknowledgments 
I would like to thank everyone at the department of Microbiology and Immunology that I 
have had the privilege to work with during my years as a research student, and whose 
presence have made this project much enjoyable. Especially I would like to express my 
sincere gratitude to: 
 
Steve Attridge, my main supervisor, for friendship, inspiration, subtle language lessons and 
for providing an excellent balance between scientific guidance and independence; 
 
Jan Holmgren, my co-supervisor, for guidance, constructive criticism and generous support 
during my seemingly endless years at the department; 
 
Bin-Ling Li, for enthusiastic and excellent technical assistance with the mice in numerous 
experiments;  
 
Gun Wallerström, Susanne Källgård and Margareta Fredrikson for high-quality technical 
assistance and friendly help; 
 
Sara Tengvall, my former room mate and friend, for stimulating discussions and valuable 
advice in various matters; 
 
Anna-Karin Östberg, Annika Lundquist, Helena Svensson, my present room mates, for nice 
conversations, laughter, ”kaka på torsdag” and for being very supportive and understanding 
during this last period; 
 
Gudrun Wiklund and Karin Ahlman for general help in the lab and for morning coffee;  
 
Carl-Fredrik Flach, Anna Lundgren, Anders Janzon and Sukanya Raghavan for friendly 
advice and discussions; 
 
Ali Harandi, Michael Lebens, Åsa Sjöling, Ulf Yrlid and for very useful comments and eager 
questioning; 
 
Staffan Nilsson and Miguel Tam for discussions regarding statistical methods; 
 
- 52 - 
Ann-Mari Svennerholm and Nils Lycke, head of the department and MIVAC respectively, for 
creating a friendly atmosphere and an excellent scientific arena; 
 
Susanne Uhlan, for always being very friendly and never complaining when I have forgotten 
about my duties on the 5th
 
 floor; 
Pernilla Ahlgren, Ivan Eisner and Lillebil Hagenberg at EBM for very professional handling 
of my mice;  
 
Ellen Marks, for friendship and revision of the English text; 
 
Clas Lilja, Erik Rehnström, Annie George Chandy, Anna Karlsson and Kristina Eriksson for 
encouraging me to seek a research career;  
 
All my friends, for still being around even though I at times have neglected you; 
 
Linnea Warger, for giving me laughter on Thursdays; 
 
My parents, brothers and extended family for always having encouraged and supported me; 
 
Jenny, for love, understanding, tremendous patience and support; 
 
This work was supported by grants from the Swedish International Development Agency, the 
Swedish Research Council for Medicine, the US NIH, the Royal Society of Arts and Sciences 
in Göteborg and Wilhelm and Martina Lundgrens Foundation. 
- 53 - 
References 
 
1. 2006. Cholera 2005. Releve epidemiologique hebdomadaire / Section d'hygiene du 
Secretariat de la Societe des Nations = Weekly epidemiological record / Health 
Section of the Secretariat of the League of Nations 81:297-307. 
2. 2008. Cholera, 2007. Releve epidemiologique hebdomadaire / Section d'hygiene du 
Secretariat de la Societe des Nations = Weekly epidemiological record / Health 
Section of the Secretariat of the League of Nations 83:269-283. 
3. 1993. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae 
O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal 
Diseases Research, Bangladesh. Lancet 342:387-390. 
4. Achtman, M., S. Schwuchow, R. Helmuth, G. Morelli, and P. A. Manning. 1978. 
Cell-cell interactions in conjugating Escherichia coli: Con− mutants and stabilization 
of mating aggregates. Molecular and General Genetics MGG 164:171-183. 
5. Albert, M. J. 1994. Vibrio cholerae O139 Bengal. Journal of clinical microbiology 
32:2345-2349. 
6. Albert, M. J., K. Alam, M. Ansaruzzaman, F. Qadri, and R. B. Sack. 1994. Lack 
of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after 
oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR. The 
Journal of infectious diseases 169:230-231. 
7. Albert, M. J., A. K. Siddique, M. S. Islam, A. S. Faruque, M. Ansaruzzaman, S. 
M. Faruque, and R. B. Sack. 1993. Large outbreak of clinical cholera due to Vibrio 
cholerae non-O1 in Bangladesh. Lancet 341:704. 
8. Anh, D. D., G. Canh do, A. L. Lopez, V. D. Thiem, P. T. Long, N. H. Son, J. Deen, 
L. von Seidlein, R. Carbis, S. H. Han, S. H. Shin, S. Attridge, J. Holmgren, and J. 
Clemens. 2007. Safety and immunogenicity of a reformulated Vietnamese bivalent 
killed, whole-cell, oral cholera vaccine in adults. Vaccine 25:1149-1155. 
9. Ansaruzzaman, M., N. A. Bhuiyan, B. G. Nair, D. A. Sack, M. Lucas, J. L. Deen, 
J. Ampuero, and C. L. Chaignat. 2004. Cholera in Mozambique, variant of Vibrio 
cholerae. Emerging infectious diseases 10:2057-2059. 
10. Ansaruzzaman, M., N. A. Bhuiyan, A. Safa, M. Sultana, A. McUamule, C. 
Mondlane, X. Y. Wang, J. L. Deen, L. von Seidlein, J. D. Clemens, M. Lucas, D. 
A. Sack, and G. Balakrish Nair. 2007. Genetic diversity of El Tor strains of Vibrio 
cholerae O1 with hybrid traits isolated from Bangladesh and Mozambique. Int J Med 
Microbiol 297:443-449. 
11. Attridge, S. R., A. Fazeli, P. A. Manning, and U. H. Stroeher. 2001. Isolation and 
characterization of bacteriophage-resistant mutants of Vibrio cholerae O139. 
Microbial pathogenesis 30:237-246. 
12. Attridge, S. R., C. Johansson, D. D. Trach, F. Qadri, and A. M. Svennerholm. 
2002. Sensitive microplate assay for detection of bactericidal antibodies to Vibrio 
cholerae O139. Clinical and diagnostic laboratory immunology 9:383-387. 
13. Attridge, S. R., P. A. Manning, J. Holmgren, and G. Jonson. 1996. Relative 
significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in 
colonization of infant mice by Vibrio cholerae El Tor. Infection and immunity 
64:3369-3373. 
14. Attridge, S. R., F. Qadri, M. J. Albert, and P. A. Manning. 2000. Susceptibility of 
Vibrio cholerae O139 to antibody-dependent, complement-mediated bacteriolysis. 
Clinical and diagnostic laboratory immunology 7:444-450. 
- 54 - 
15. Attridge, S. R., and D. Rowley. 1983. The role of the flagellum in the adherence of 
Vibrio cholerae. The Journal of infectious diseases 147:864-872. 
16. Attridge, S. R., G. Wallerstrom, F. Qadri, and A. M. Svennerholm. 2004. 
Detection of antibodies to toxin-coregulated pili in sera from cholera patients. 
Infection and immunity 72:1824-1827. 
17. Barua, D. 1972. The global epidemiology of cholera in recent years. Proceedings of 
the Royal Society of Medicine 65:423-428. 
18. Benitez, J. A., R. G. Spelbrink, A. Silva, T. E. Phillips, C. M. Stanley, M. 
Boesman-Finkelstein, and R. A. Finkelstein. 1997. Adherence of Vibrio cholerae to 
cultured differentiated human intestinal cells: an in vitro colonization model. Infection 
and immunity 65:3474-3477. 
19. Bik, E. M., A. E. Bunschoten, R. D. Gouw, and F. R. Mooi. 1995. Genesis of the 
novel epidemic Vibrio cholerae O139 strain: evidence for horizontal transfer of genes 
involved in polysaccharide synthesis. The EMBO journal 14:209-216. 
20. Boin, M. A., M. J. Austin, and C. C. Hase. 2004. Chemotaxis in Vibrio cholerae. 
FEMS microbiology letters 239:1-8. 
21. Booth, B. A., M. Boesman-Finkelstein, and R. A. Finkelstein. 1984. Vibrio 
cholerae hemagglutinin/protease nicks cholera enterotoxin. Infection and immunity 
45:558-560. 
22. Booth, B. A., M. Boesman-Finkelstein, and R. A. Finkelstein. 1983. Vibrio 
cholerae soluble hemagglutinin/protease is a metalloenzyme. Infection and immunity 
42:639-644. 
23. Boyd, E. F., and M. K. Waldor. 1999. Alternative mechanism of cholera toxin 
acquisition by Vibrio cholerae: generalized transduction of CTXPhi by bacteriophage 
CP-T1. Infection and immunity 67:5898-5905. 
24. Butterton, J. R., E. T. Ryan, R. A. Shahin, and S. B. Calderwood. 1996. 
Development of a germfree mouse model of Vibrio cholerae infection. Infection and 
immunity 64:4373-4377. 
25. Calain, P., J. P. Chaine, E. Johnson, M. L. Hawley, M. J. O'Leary, H. Oshitani, 
and C. L. Chaignat. 2004. Can oral cholera vaccination play a role in controlling a 
cholera outbreak? Vaccine 22:2444-2451. 
26. Carpenter, C. C., R. B. Sack, J. C. Feeley, and R. W. Steenberg. 1968. Site and 
characteristics of electrolyte loss and effect of intraluminal glucose in experimental 
canine cholera. The Journal of clinical investigation 47:1210-1220. 
27. Chatterjee, S. N., and K. Chaudhuri. 2003. Lipopolysaccharides of Vibrio cholerae. 
I. Physical and chemical characterization. Biochimica et biophysica acta 1639:65-79. 
28. Chatterjee, S. N., and K. Chaudhuri. 2006. Lipopolysaccharides of Vibrio cholerae: 
III. Biological functions. Biochimica et biophysica acta 1762:1-16. 
29. Chen, I., T. M. Finn, L. Yanqing, Q. Guoming, R. Rappuoli, and M. Pizza. 1998. 
A recombinant live attenuated strain of Vibrio cholerae induces immunity against 
tetanus toxin and Bordetella pertussis tracheal colonization factor. Infection and 
immunity 66:1648-1653. 
30. Clemens, J. D., J. R. Harris, D. A. Sack, J. Chakraborty, F. Ahmed, B. F. 
Stanton, M. U. Khan, B. A. Kay, N. Huda, M. R. Khan, and et al. 1988. Field trial 
of oral cholera vaccines in Bangladesh: results of one year of follow-up. The Journal 
of infectious diseases 158:60-69. 
31. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, M. R. Khan, S. Huda, F. 
Ahmed, J. Gomes, M. R. Rao, A. M. Svennerholm, and et al. 1989. ABO blood 
groups and cholera: new observations on specificity of risk and modification of 
vaccine efficacy. The Journal of infectious diseases 159:770-773. 
- 55 - 
32. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, M. R. Khan, B. F. 
Stanton, B. A. Kay, M. U. Khan, M. Yunus, W. Atkinson, and et al. 1986. Field 
trial of oral cholera vaccines in Bangladesh. Lancet 2:124-127. 
33. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, P. K. Neogy, B. Stanton, 
N. Huda, M. U. Khan, B. A. Kay, M. R. Khan, and et al. 1988. Cross-protection by 
B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile 
toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. 
The Journal of infectious diseases 158:372-377. 
34. Clemens, J. D., D. A. Sack, J. R. Harris, F. Van Loon, J. Chakraborty, F. Ahmed, 
M. R. Rao, M. R. Khan, M. Yunus, N. Huda, and et al. 1990. Field trial of oral 
cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335:270-
273. 
35. Clemens, J. D., F. van Loon, D. A. Sack, J. Chakraborty, M. R. Rao, F. Ahmed, J. 
R. Harris, M. R. Khan, M. Yunus, S. Huda, and et al. 1991. Field trial of oral 
cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers 
of the risk of cholera. The Journal of infectious diseases 163:1235-1242. 
36. Cohen, M. B., R. A. Giannella, G. A. Losonsky, D. R. Lang, S. Parker, J. A. 
Hawkins, C. Gunther, and G. A. Schiff. 1999. Validation and characterization of a 
human volunteer challenge model for cholera by using frozen bacteria of the new 
Vibrio cholerae epidemic serotype, O139. Infection and immunity 67:6346-6349. 
37. Crean, T. I., M. John, S. B. Calderwood, and E. T. Ryan. 2000. Optimizing the 
germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and 
vector strains. Infection and immunity 68:977-981. 
38. Das, M., A. K. Chopra, J. M. Cantu, and J. W. Peterson. 1998. Antisera to selected 
outer membrane proteins of Vibrio cholerae protect against challenge with 
homologous and heterologous strains of V. cholerae. FEMS immunology and medical 
microbiology 22:303-308. 
39. Davis, B. M., and M. K. Waldor. 2003. Filamentous phages linked to virulence of 
Vibrio cholerae. Current opinion in microbiology 6:35-42. 
40. De, S. N. 1959. Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. 
Nature 183:1533-1534. 
41. De, S. N., and D. N. Chatterje. 1953. An experimental study of the mechanism of 
action of Vibriod cholerae on the intestinal mucous membrane. The Journal of 
pathology and bacteriology 66:559-562. 
42. Deen, J. L., L. von Seidlein, D. Sur, M. Agtini, M. E. Lucas, A. L. Lopez, D. R. 
Kim, M. Ali, and J. D. Clemens. 2008. The high burden of cholera in children: 
comparison of incidence from endemic areas in Asia and Africa. PLoS neglected 
tropical diseases 2:e173. 
43. Delacroix, D. L., G. Furtado-Barreira, J. Rahier, C. Dive, and J. P. Vaerman. 
1984. Immunohistochemical localization of secretory component in the liver of guinea 
pigs and dogs versus rats, rabbits, and mice. Scandinavian journal of immunology 
19:425-434. 
44. Dutta, N. K., and M. K. Habbu. 1955. Experimental cholera in infant rabbits: a 
method for chemotherapeutic investigation. British journal of pharmacology and 
chemotherapy 10:153-159. 
45. Dutta, N. K., M. V. Panse, and D. R. Kulkarni. 1959. Role of cholera a toxin in 
experimental cholera. Journal of bacteriology 78:594-595. 
46. Elson, C. O., and W. Ealding. 1984. Generalized systemic and mucosal immunity in 
mice after mucosal stimulation with cholera toxin. J Immunol 132:2736-2741. 
- 56 - 
47. Faruque, A. S., D. Mahalanabis, S. S. Hoque, and M. J. Albert. 1994. The 
relationship between ABO blood groups and susceptibility to diarrhea due to Vibrio 
cholerae 0139. Clin Infect Dis 18:827-828. 
48. Faruque, S. M., M. J. Albert, and J. J. Mekalanos. 1998. Epidemiology, genetics, 
and ecology of toxigenic Vibrio cholerae. Microbiol Mol Biol Rev 62:1301-1314. 
49. Faruque, S. M., N. Chowdhury, M. Kamruzzaman, Q. S. Ahmad, A. S. Faruque, 
M. A. Salam, T. Ramamurthy, G. B. Nair, A. Weintraub, and D. A. Sack. 2003. 
Reemergence of epidemic Vibrio cholerae O139, Bangladesh. Emerging infectious 
diseases 9:1116-1122. 
50. Faruque, S. M., I. B. Naser, M. J. Islam, A. S. Faruque, A. N. Ghosh, G. B. Nair, 
D. A. Sack, and J. J. Mekalanos. 2005. Seasonal epidemics of cholera inversely 
correlate with the prevalence of environmental cholera phages. Proceedings of the 
National Academy of Sciences of the United States of America 102:1702-1707. 
51. Finkelstein, R. A., M. Boesman-Finkelstein, and P. Holt. 1983. Vibrio cholerae 
hemagglutinin/lectin/protease hydrolyzes fibronectin and ovomucin: F.M. Burnet 
revisited. Proceedings of the National Academy of Sciences of the United States of 
America 80:1092-1095. 
52. Flach, C. F., F. Qadri, T. R. Bhuiyan, N. H. Alam, E. Jennische, I. Lonnroth, and 
J. Holmgren. 2007. Broad up-regulation of innate defense factors during acute 
cholera. Infection and immunity 75:2343-2350. 
53. Fuerst, J. A., and J. W. Perry. 1988. Demonstration of lipopolysaccharide on 
sheathed flagella of Vibrio cholerae O:1 by protein A-gold immunoelectron 
microscopy. Journal of bacteriology 170:1488-1494. 
54. Gaffga, N. H., R. V. Tauxe, and E. D. Mintz. 2007. Cholera: a new homeland in 
Africa? The American journal of tropical medicine and hygiene 77:705-713. 
55. Garcia, L., M. D. Jidy, H. Garcia, B. L. Rodriguez, R. Fernandez, G. Ano, B. 
Cedre, T. Valmaseda, E. Suzarte, M. Ramirez, Y. Pino, J. Campos, J. Menendez, 
R. Valera, D. Gonzalez, I. Gonzalez, O. Perez, T. Serrano, M. Lastre, F. Miralles, 
J. Del Campo, J. L. Maestre, J. L. Perez, A. Talavera, A. Perez, K. Marrero, T. 
Ledon, and R. Fando. 2005. The vaccine candidate Vibrio cholerae 638 is protective 
against cholera in healthy volunteers. Infection and immunity 73:3018-3024. 
56. Glass, R. I., S. Becker, M. I. Huq, B. J. Stoll, M. U. Khan, M. H. Merson, J. V. 
Lee, and R. E. Black. 1982. Endemic cholera in rural Bangladesh, 1966-1980. 
American journal of epidemiology 116:959-970. 
57. Glass, R. I., A. M. Svennerholm, M. R. Khan, S. Huda, M. I. Huq, and J. 
Holmgren. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: 
association of serum antibody levels with protection. The Journal of infectious 
diseases 151:236-242. 
58. Goel, A. K., M. Jain, P. Kumar, S. Bhadauria, D. V. Kmboj, and L. Singh. 2008. 
A new variant of Vibrio cholerae O1 El Tor causing cholera in India. The Journal of 
infection 57:280-281. 
59. Graves, P., J. Deeks, V. Demicheli, M. Pratt, and T. Jefferson. 2000. Vaccines for 
preventing cholera. Cochrane database of systematic reviews (Online):CD000974. 
60. Gustafsson, B., and T. Holme. 1983. Monoclonal antibodies against group- and type-
specific lipopolysaccharide antigens of Vibrio cholerae O:1. Journal of clinical 
microbiology 18:480-485. 
61. Hall, R. H., G. Losonsky, A. P. Silveira, R. K. Taylor, J. J. Mekalanos, N. D. 
Witham, and M. M. Levine. 1991. Immunogenicity of Vibrio cholerae O1 toxin-
coregulated pili in experimental and clinical cholera. Infection and immunity 59:2508-
2512. 
- 57 - 
62. Harris, J. B., R. C. Larocque, F. Chowdhury, A. I. Khan, T. Logvinenko, A. S. 
Faruque, E. T. Ryan, F. Qadri, and S. B. Calderwood. 2008. Susceptibility to 
Vibrio cholerae Infection in a Cohort of Household Contacts of Patients with Cholera 
in Bangladesh. PLoS neglected tropical diseases 2:e221. 
63. Harrison, L. M., P. Rallabhandi, J. Michalski, X. Zhou, S. R. Steyert, S. N. Vogel, 
and J. B. Kaper. 2008. Vibrio cholerae flagellins induce Toll-like receptor 5-
mediated interleukin-8 production through mitogen-activated protein kinase and NF-
kappaB activation. Infection and immunity 76:5524-5534. 
64. Hase, C. C., and R. A. Finkelstein. 1991. Cloning and nucleotide sequence of the 
Vibrio cholerae hemagglutinin/protease (HA/protease) gene and construction of an 
HA/protease-negative strain. Journal of bacteriology 173:3311-3317. 
65. Herrington, D. A., R. H. Hall, G. Losonsky, J. J. Mekalanos, R. K. Taylor, and 
M. M. Levine. 1988. Toxin, toxin-coregulated pili, and the toxR regulon are essential 
for Vibrio cholerae pathogenesis in humans. The Journal of experimental medicine 
168:1487-1492. 
66. Holmgren, J., and C. Bergquist. 2004. Oral B subunit-killed whole cell cholera 
vaccine. p. 499-509 In M. Levine, J. Kaper , R. Rappuoli ,M. Liu, M. Good , (ed.), 
New generation vaccines, 3rd ed, rev., and expanded. ed. Marcel Dekker, New York. 
67. Holmgren, J., and J. B. Kaper. 2008 in press. Oral cholera vaccines. In: M. Levine, 
J. Kaper , R. Rappuoli ,M. Liu, M. Good , (ed.), New generation vaccines, 4th ed. 
Marcel Dekker, New York. 
68. Holmgren, J., and L. Lindholm. 1976. Cholera toxin, ganglioside receptors and the 
immune response. Immunological communications 5:737-756. 
69. Holmgren, J., I. Lonnroth, and L. Svennerholm. 1973. Tissue receptor for cholera 
exotoxin: postulated structure from studies with GM1 ganglioside and related 
glycolipids. Infection and immunity 8:208-214. 
70. Holmgren, J., A. M. Svennerholm, I. Lonnroth, M. Fall-Persson, B. Markman, 
and H. Lundbeck. 1977. Development of improved cholera vaccine based on subunit 
toxoid. Nature 269:602-604. 
71. Holmgren, J., A. M. Svennerholm, O. Ouchterlony, A. Anderson, G. 
Walletstrom, and U. Westerberg-Berndtsson. 1975. Antitoxic immunity in 
experimental cholera: protection, and serum and local antibody responses in rabbits 
after enteral and parenteral immunization. Infection and immunity 12:1331-1340. 
72. Hornick, R. B., S. I. Music, R. Wenzel, R. Cash, J. P. Libonati, M. J. Snyder, and 
T. E. Woodward. 1971. The Broad Street pump revisited: response of volunteers to 
ingested cholera vibrios. Bulletin of the New York Academy of Medicine 47:1181-
1191. 
73. Hsiao, A., Z. Liu, A. Joelsson, and J. Zhu. 2006. Vibrio cholerae virulence 
regulator-coordinated evasion of host immunity. Proceedings of the National 
Academy of Sciences of the United States of America 103:14542-14547. 
74. Hsiao, A., K. Toscano, and J. Zhu. 2008. Post-transcriptional cross-talk between 
pro- and anti-colonization pili biosynthesis systems in Vibrio cholerae. Molecular 
microbiology 67:849-860. 
75. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1986. Saliva, breast milk, and 
serum antibody responses as indirect measures of intestinal immunity after oral 
cholera vaccination or natural disease. Journal of clinical microbiology 24:203-209. 
76. Johnson, J. A., P. Panigrahi, and J. G. Morris, Jr. 1992. Non-O1 Vibrio cholerae 
NRT36S produces a polysaccharide capsule that determines colony morphology, 
serum resistance, and virulence in mice. Infection and immunity 60:864-869. 
- 58 - 
77. Jonson, G., J. Holmgren, and A. M. Svennerholm. 1991. Epitope differences in 
toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1. Microbial 
pathogenesis 11:179-188. 
78. Kaper, J. B., J. G. Morris, Jr., and M. M. Levine. 1995. Cholera. Clinical 
microbiology reviews 8:48-86. 
79. Karaolis, D. K., J. A. Johnson, C. C. Bailey, E. C. Boedeker, J. B. Kaper, and P. 
R. Reeves. 1998. A Vibrio cholerae pathogenicity island associated with epidemic and 
pandemic strains. Proceedings of the National Academy of Sciences of the United 
States of America 95:3134-3139. 
80. Karaolis, D. K., S. Somara, D. R. Maneval, Jr., J. A. Johnson, and J. B. Kaper. 
1999. A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage 
receptor in cholera bacteria. Nature 399:375-379. 
81. Kateley, J. R., L. Kasarov, and H. Friedman. 1975. Modulation of in vivo antibody 
responses by cholera toxin. J Immunol 114:81-84. 
82. Kenner, J. R., T. S. Coster, D. N. Taylor, A. F. Trofa, M. Barrera-Oro, T. 
Hyman, J. M. Adams, D. T. Beattie, K. P. Killeen, D. R. Spriggs, and et al. 1995. 
Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. 
The Journal of infectious diseases 172:1126-1129. 
83. King, A. A., E. L. Ionides, M. Pascual, and M. J. Bouma. 2008. Inapparent 
infections and cholera dynamics. Nature 454:877-880. 
84. Kirn, T. J., M. J. Lafferty, C. M. Sandoe, and R. K. Taylor. 2000. Delineation of 
pilin domains required for bacterial association into microcolonies and intestinal 
colonization by Vibrio cholerae. Molecular microbiology 35:896-910. 
85. Koch, R. 1884. An adress on cholera and its bacillus. The British Medical Journal 
2:403-407. 
86. Kovach, M. E., M. D. Shaffer, and K. M. Peterson. 1996. A putative integrase gene 
defines the distal end of a large cluster of ToxR-regulated colonization genes in Vibrio 
cholerae. Microbiology (Reading, England) 142 ( Pt 8):2165-2174. 
87. Lee, S. H., S. M. Butler, and A. Camilli. 2001. Selection for in vivo regulators of 
bacterial virulence. Proceedings of the National Academy of Sciences of the United 
States of America 98:6889-6894. 
88. Levine, M. M., R. E. Black, M. L. Clements, L. Cisneros, D. R. Nalin, and C. R. 
Young. 1981. Duration of infection-derived immunity to cholera. The Journal of 
infectious diseases 143:818-820. 
89. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements. 1983. New 
knowledge on pathogenesis of bacterial enteric infections as applied to vaccine 
development. Microbiological reviews 47:510-550. 
90. Levine, M. M., J. B. Kaper, D. Herrington, J. Ketley, G. Losonsky, C. O. Tacket, 
B. Tall, and S. Cryz. 1988. Safety, immunogenicity, and efficacy of recombinant live 
oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 2:467-470. 
91. Levine, M. M., J. B. Kaper, D. Herrington, G. Losonsky, J. G. Morris, M. L. 
Clements, R. E. Black, B. Tall, and R. Hall. 1988. Volunteer studies of deletion 
mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infection and 
immunity 56:161-167. 
92. Levine, M. M., and C. O. Tacket. 1994. Recombinant live cholera vaccines, p. 395-
413. In I. K Wachsmuth, P. A. Blake and O. Olsvik (ed.), Vibrio cholerae and cholera: 
molecular to global perspectives. ASM Press, Washington, D.C. 
93. Li, J., M. S. Lim, S. Li, M. Brock, M. E. Pique, V. L. Woods, Jr., and L. Craig. 
2008. Vibrio cholerae toxin-coregulated pilus structure analyzed by 
hydrogen/deuterium exchange mass spectrometry. Structure 16:137-148. 
- 59 - 
94. Longini, I. M., Jr., M. Yunus, K. Zaman, A. K. Siddique, R. B. Sack, and A. 
Nizam. 2002. Epidemic and endemic cholera trends over a 33-year period in 
Bangladesh. The Journal of infectious diseases 186:246-251. 
95. Lonnroth, I., and J. Holmgren. 1973. Subunit structure of cholera toxin. Journal of 
general microbiology 76:417-427. 
96. Lopez, A. L., J. D. Clemens, J. Deen, and L. Jodar. 2008. Cholera vaccines for the 
developing world. Human vaccines 4:165-169. 
97. Losonsky, G. A., J. Yunyongying, V. Lim, M. Reymann, Y. L. Lim, S. S. 
Wasserman, and M. M. Levine. 1996. Factors influencing secondary vibriocidal 
immune responses: relevance for understanding immunity to cholera. Infection and 
immunity 64:10-15. 
98. Lucas, M. E., J. L. Deen, L. von Seidlein, X. Y. Wang, J. Ampuero, M. Puri, M. 
Ali, M. Ansaruzzaman, J. Amos, A. Macuamule, P. Cavailler, P. J. Guerin, C. 
Mahoudeau, P. Kahozi-Sangwa, C. L. Chaignat, A. Barreto, F. F. Songane, and J. 
D. Clemens. 2005. Effectiveness of mass oral cholera vaccination in Beira, 
Mozambique. The New England journal of medicine 352:757-767. 
99. Lycke, N. 2005. From toxin to adjuvant: basic mechanisms for the control of mucosal 
IgA immunity and tolerance. Immunology letters 97:193-198. 
100. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut 
mucosal immune responses to orally presented antigens. Immunology 59:301-308. 
101. Lycke, N., A. M. Svennerholm, and J. Holmgren. 1986. Strong biotype and 
serotype cross-protective antibacterial and antitoxic immunity in rabbits after cholera 
infection. Microbial pathogenesis 1:361-371. 
102. Macpherson, A. J., D. Gatto, E. Sainsbury, G. R. Harriman, H. Hengartner, and 
R. M. Zinkernagel. 2000. A primitive T cell-independent mechanism of intestinal 
mucosal IgA responses to commensal bacteria. Science (New York, N.Y 288:2222-
2226. 
103. Mahalanabis, D., A. L. Lopez, D. Sur, J. Deen, B. Manna, S. Kanungo, L. von 
Seidlein, R. Carbis, S. H. Han, S. H. Shin, S. Attridge, R. Rao, J. Holmgren, J. 
Clemens, and S. K. Bhattacharya. 2008. A randomized, placebo-controlled trial of 
the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera 
endemic area in Kolkata, India. PLoS ONE 3:e2323. 
104. McCormack, W. M., M. S. Islam, M. Fahimuddin, and W. H. Mosley. 1969. A 
community study of inapparent cholera infections. American journal of epidemiology 
89:658-664. 
105. Merrell, D. S., S. M. Butler, F. Qadri, N. A. Dolganov, A. Alam, M. B. Cohen, S. 
B. Calderwood, G. K. Schoolnik, and A. Camilli. 2002. Host-induced epidemic 
spread of the cholera bacterium. Nature 417:642-645. 
106. Minh, N. B., J. H. Lee, N. T. Cuong, S. Y. Choi, N. T. Hien, D. D. Anh, H. R. Lee, 
M. Ansaruzzaman, H. P. Endtz, J. Chun, A. L. Lopez, C. Czerkinsky, J. D. 
Clemens, and D. W. Kim. 2009. Cholera outbreaks caused by an altered Vibrio 
cholerae O1 El Tor biotype strain producing classical type cholera toxin B in Vietnam 
2007-2008. Journal of clinical microbiology. 
107. Moreau, M. C., R. Ducluzeau, D. Guy-Grand, and M. C. Muller. 1978. Increase in 
the population of duodenal immunoglobulin A plasmocytes in axenic mice associated 
with different living or dead bacterial strains of intestinal origin. Infection and 
immunity 21:532-539. 
108. Morris, J. G., Jr., G. E. Losonsky, J. A. Johnson, C. O. Tacket, J. P. Nataro, P. 
Panigrahi, and M. M. Levin. 1995. Clinical and immunologic characteristics of 
- 60 - 
Vibrio cholerae O139 Bengal infection in North American volunteers. The Journal of 
infectious diseases 171:903-908. 
109. Mosley, W. H., S. Ahmad, A. S. Benenson, and A. Ahmed. 1968. The relationship 
of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera 
patients. Bulletin of the World Health Organization 38:777-785. 
110. Mosley, W. H., W. M. McCormack, A. Ahmed, A. K. Chowdhury, and R. K. 
Barui. 1969. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. 
Results of the serological surveys in the study population--the relationship of case rate 
to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. 
Bulletin of the World Health Organization 40:187-197. 
111. Nair, G. B., F. Qadri, J. Holmgren, A. M. Svennerholm, A. Safa, N. A. Bhuiyan, 
Q. S. Ahmad, S. M. Faruque, A. S. Faruque, Y. Takeda, and D. A. Sack. 2006. 
Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. Journal of 
clinical microbiology 44:4211-4213. 
112. Nair, G. B., T. Ramamurthy, S. K. Bhattacharya, A. K. Mukhopadhyay, S. Garg, 
M. K. Bhattacharya, T. Takeda, T. Shimada, Y. Takeda, and B. C. Deb. 1994. 
Spread of Vibrio cholerae O139 Bengal in India. The Journal of infectious diseases 
169:1029-1034. 
113. Nandy, R. K., M. J. Albert, and A. C. Ghose. 1996. Serum antibacterial and 
antitoxin responses in clinical cholera caused by Vibrio cholerae O139 Bengal and 
evaluation of their importance in protection. Vaccine 14:1137-1142. 
114. Neoh, S. H., and D. Rowley. 1970. The antigens of Vibrio cholerae involved in the 
vibriocidal action of antibody and complement. The Journal of infectious diseases 
121:505-513. 
115. Nygren, E., J. Holmgren, and S. R. Attridge. 2008. Murine antibody responses 
following systemic or mucosal immunization with viable or inactivated Vibrio 
cholerae. Vaccine 26:6784-6790. 
116. Olivier, V., G. K. Haines, 3rd, Y. Tan, and K. J. Satchell. 2007. Hemolysin and the 
multifunctional autoprocessing RTX toxin are virulence factors during intestinal 
infection of mice with Vibrio cholerae El Tor O1 strains. Infection and immunity 
75:5035-5042. 
117. Olivier, V., N. H. Salzman, and K. J. Satchell. 2007. Prolonged colonization of mice 
by Vibrio cholerae El Tor O1 depends on accessory toxins. Infection and immunity 
75:5043-5051. 
118. Perez, J. L., R. Acevedo, A. Callico, Y. Fernandez, B. Cedre, G. Ano, L. 
Gonzalez, G. Falero, A. Talavera, O. Perez, and L. Garcia. 2009. A 
proteoliposome based formulation administered by the nasal route produces 
vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. 
Vaccine 27:205-212. 
119. Pierce, N. F., W. C. Cray, Jr., and J. B. Sacci, Jr. 1982. Oral immunization of dogs 
with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic 
protection by antitoxic and antibacterial mechanisms. Infection and immunity 37:687-
694. 
120. Pierce, N. F., W. C. Cray, Jr., J. B. Sacci, Jr., J. P. Craig, R. Germanier, and E. 
Furer. 1983. Procholeragenoid: a safe and effective antigen for oral immunization 
against experimental cholera. Infection and immunity 40:1112-1118. 
121. Qadri, F., T. R. Bhuiyan, K. K. Dutta, R. Raqib, M. S. Alam, N. H. Alam, A. M. 
Svennerholm, and M. M. Mathan. 2004. Acute dehydrating disease caused by 
Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and 
inflammatory mediators at the mucosal surface of the gut. Gut 53:62-69. 
- 61 - 
122. Qadri, F., G. Jonson, Y. A. Begum, C. Wenneras, M. J. Albert, M. A. Salam, and 
A. M. Svennerholm. 1997. Immune response to the mannose-sensitive hemagglutinin 
in patients with cholera due to Vibrio cholerae O1 and O0139. Clinical and diagnostic 
laboratory immunology 4:429-434. 
123. Qadri, F., R. Raqib, F. Ahmed, T. Rahman, C. Wenneras, S. Kumar Das, N. H. 
Alam, M. M. Mathan, and A.-M. Svennerholm. 2002. Increased Levels of 
Inflammatory Mediators in Children and Adults Infected with Vibrio cholerae O1 and 
O139, p. 221-229. vol. 9. 
124. Qadri, F., E. T. Ryan, A. S. Faruque, F. Ahmed, A. I. Khan, M. M. Islam, S. M. 
Akramuzzaman, D. A. Sack, and S. B. Calderwood. 2003. Antigen-specific 
immunoglobulin A antibodies secreted from circulating B cells are an effective marker 
for recent local immune responses in patients with cholera: comparison to antibody-
secreting cell responses and other immunological markers. Infection and immunity 
71:4808-4814. 
125. Qadri, F., C. Wenneras, M. J. Albert, J. Hossain, K. Mannoor, Y. A. Begum, G. 
Mohi, M. A. Salam, R. B. Sack, and A. M. Svennerholm. 1997. Comparison of 
immune responses in patients infected with Vibrio cholerae O139 and O1. Infection 
and immunity 65:3571-3576. 
126. Ramamurthy, T., S. Yamasaki, Y. Takeda, and G. B. Nair. 2003. Vibrio cholerae 
O139 Bengal: odyssey of a fortuitous variant. Microbes and infection / Institut Pasteur 
5:329-344. 
127. Rappuoli, R., M. Pizza, G. Douce, and G. Dougan. 1999. Structure and mucosal 
adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunology 
today 20:493-500. 
128. Reidl, J., and K. E. Klose. 2002. Vibrio cholerae and cholera: out of the water and 
into the host. FEMS microbiology reviews 26:125-139. 
129. Rhine, J. A., and R. K. Taylor. 1994. TcpA pilin sequences and colonization 
requirements for O1 and O139 Vibrio cholerae. Molecular microbiology 13:1013-
1020. 
130. Richardson, K. 1991. Roles of motility and flagellar structure in pathogenicity of 
Vibrio cholerae: analysis of motility mutants in three animal models. Infection and 
immunity 59:2727-2736. 
131. Richardson, S. H. 1994. Animal models in cholera research, p. 203-208. In I. K 
Wachsmuth, P. A. Blake and O. Olsvik (ed.), Vibrio cholerae and cholera: molecular 
to global perspectives. ASM Press, Washington, D.C. 
132. Richie, E. E., N. H. Punjabi, Y. Y. Sidharta, K. K. Peetosutan, M. M. Sukandar, 
S. S. Wasserman, M. M. Lesmana, F. F. Wangsasaputra, S. S. Pandam, M. M. 
Levine, P. P. O'Hanley, S. J. Cryz, and C. H. Simanjuntak. 2000. Efficacy trial of 
single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a 
cholera-endemic area. Vaccine 18:2399-2410. 
133. Sack, D. A., R. B. Sack, G. B. Nair, and A. K. Siddique. 2004. Cholera. Lancet 
363:223-233. 
134. Sack, G. H., Jr., N. F. Pierce, K. N. Hennessey, R. C. Mitra, R. B. Sack, and D. N. 
Mazumder. 1972. Gastric acidity in cholera and noncholera diarrhoea. Bulletin of the 
World Health Organization 47:31-36. 
135. Sack, R. B., and C. C. Carpenter. 1969. Experimental canine cholera. I. 
Development of the model. The Journal of infectious diseases 119:138-149. 
136. Sack, R. B., and C. E. Miller. 1969. Progressive changes of Vibrio serotypes in 
germ-free mice infected with Vibrio cholerae. Journal of bacteriology 99:688-695. 
- 62 - 
137. Saha, D., R. C. LaRocque, A. I. Khan, J. B. Harris, Y. A. Begum, S. M. 
Akramuzzaman, A. S. Faruque, E. T. Ryan, F. Qadri, and S. B. Calderwood. 
2004. Incomplete correlation of serum vibriocidal antibody titer with protection from 
Vibrio cholerae infection in urban Bangladesh. The Journal of infectious diseases 
189:2318-2322. 
138. Samadi, A. R., M. I. Huq, N. Shahid, M. U. Khan, A. Eusof, A. S. Rahman, M. 
Yunus, and A. S. Faruque. 1983. Classical Vibrio cholerae biotype displaces EL tor 
in Bangladesh. Lancet 1:805-807. 
139. Sanchez, J., and J. Holmgren. 2008. Cholera toxin structure, gene regulation and 
pathophysiological and immunological aspects. Cell Mol Life Sci 65:1347-1360. 
140. Sanchez, J., and J. Holmgren. 2005. Virulence factors, pathogenesis and vaccine 
protection in cholera and ETEC diarrhea. Current opinion in immunology 17:388-398. 
141. Sandkvist, M., L. O. Michel, L. P. Hough, V. M. Morales, M. Bagdasarian, M. 
Koomey, V. J. DiRita, and M. Bagdasarian. 1997. General secretion pathway (eps) 
genes required for toxin secretion and outer membrane biogenesis in Vibrio cholerae. 
Journal of bacteriology 179:6994-7003. 
142. Satchell, K. J. 2003. Activation and suppression of the proinflammatory immune 
response by Vibrio cholerae toxins. Microbes and infection / Institut Pasteur 5:1241-
1247. 
143. Scerpella, E. G., J. L. Sanchez, I. J. Mathewson, J. V. Torres-Cordero, J. C. 
Sadoff, A. M. Svennerholm, H. L. DuPont, D. N. Taylor, and C. D. Ericsson. 
1995. Safety, Immunogenicity, and Protective Efficacy of the Whole-
Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' 
Diarrhea. J Travel Med 2:22-27. 
144. Schild, S., E. J. Nelson, and A. Camilli. 2008. Immunization with Vibrio cholerae 
outer membrane vesicles induces protective immunity in mice. Infection and immunity 
76:4554-4563. 
145. Sciortino, C. V. 1989. Protection against infection with Vibrio cholerae by passive 
transfer of monoclonal antibodies to outer membrane antigens. The Journal of 
infectious diseases 160:248-252. 
146. Sciortino, C. V. 1996. Protection against mortality due to Vibrio cholerae infection in 
infant rabbits caused by immunization of mothers with cholera protective antigen. 
Journal of diarrhoeal diseases research 14:16-26. 
147. Sears, S. D., K. Richardson, C. Young, C. D. Parker, and M. M. Levine. 1984. 
Evaluation of the human immune response to outer membrane proteins of Vibrio 
cholerae. Infection and immunity 44:439-444. 
148. Sengupta, D. K., T. K. Sengupta, and A. C. Ghose. 1992. Major outer membrane 
proteins of Vibrio cholerae and their role in induction of protective immunity through 
inhibition of intestinal colonization. Infection and immunity 60:4848-4855. 
149. Sengupta, P. G., B. K. Sircar, S. K. Mandal, A. K. Mukhopadhyay, G. B. Nair, D. 
N. Gupta, S. Ghosh, N. C. Saha, B. C. Deb, S. N. Sikder, and et al. 1995. 
Epidemiology of Vibrio cholerae O139 with special reference to intrafamilial 
transmission in Calcutta. The Journal of infection 31:45-47. 
150. Shamsuzzaman, S., T. Ahmed, K. Mannoor, Y. A. Begum, P. K. Bardhan, R. B. 
Sack, D. A. Sack, A. M. Svennerholm, J. Holmgren, and F. Qadri. 2009. Robust 
gut associated vaccine-specific antibody-secreting cell responses are detected at the 
mucosal surface of Bangladeshi subjects after immunization with an oral killed 
bivalent V. cholerae O1/O139 whole cell cholera vaccine: Comparison with other 
mucosal and systemic responses. Vaccine. 
- 63 - 
151. Sharma, D. P., C. Thomas, R. H. Hall, M. M. Levine, and S. R. Attridge. 1989. 
Significance of toxin-coregulated pili as protective antigens of Vibrio cholerae in the 
infant mouse model. Vaccine 7:451-456. 
152. Sharma, N. C., P. K. Mandal, R. Dhillon, and M. Jain. 2007. Changing profile of 
Vibrio cholerae O1, O139 in Delhi & its periphery (2003-2005). The Indian journal of 
medical research 125:633-640. 
153. Silva, A. J., G. J. Leitch, A. Camilli, and J. A. Benitez. 2006. Contribution of 
hemagglutinin/protease and motility to the pathogenesis of El Tor biotype cholera. 
Infection and immunity 74:2072-2079. 
154. Silva, A. J., A. Mohan, and J. A. Benitez. 2003. Cholera vaccine candidate 638: 
intranasal immunogenicity and expression of a foreign antigen from the pulmonary 
pathogen Coccidioides immitis. Vaccine 21:4715-4721. 
155. Silva, A. J., K. Pham, and J. A. Benitez. 2003. Haemagglutinin/protease expression 
and mucin gel penetration in El Tor biotype Vibrio cholerae. Microbiology (Reading, 
England) 149:1883-1891. 
156. Sperandio, V., J. A. Giron, W. D. Silveira, and J. B. Kaper. 1995. The OmpU outer 
membrane protein, a potential adherence factor of Vibrio cholerae. Infection and 
immunity 63:4433-4438. 
157. Spira, W. M., R. B. Sack, and J. L. Froehlich. 1981. Simple adult rabbit model for 
Vibrio cholerae and enterotoxigenic Escherichia coli diarrhea. Infection and immunity 
32:739-747. 
158. Stewart-Tull, D. E. 2001. Vaba, Haiza, Kholera, Foklune or Cholera: in any language 
still the disease of seven pandemics. Journal of applied microbiology 91:580-591. 
159. Stroeher, U. H., K. E. Jedani, B. K. Dredge, R. Morona, M. H. Brown, L. E. 
Karageorgos, M. J. Albert, and P. A. Manning. 1995. Genetic rearrangements in 
the rfb regions of Vibrio cholerae O1 and O139. Proceedings of the National 
Academy of Sciences of the United States of America 92:10374-10378. 
160. Sun, D. X., J. J. Mekalanos, and R. K. Taylor. 1990. Antibodies directed against the 
toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant 
mouse experimental cholera model. The Journal of infectious diseases 161:1231-1236. 
161. Svennerholm, A., S. Lange, and J. Holmgren. 1978. Correlation between intestinal 
synthesis of specific immunoglobulin A and protection against experimental cholera in 
mice. Infection and immunity 21:1-6. 
162. Svennerholm, A. M., and J. Holmgren. 1976. Synergistic protective effect in rabbits 
of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infection 
and immunity 13:735-740. 
163. Tacket, C. O., M. B. Cohen, S. S. Wasserman, G. Losonsky, S. Livio, K. Kotloff, 
R. Edelman, J. B. Kaper, S. J. Cryz, R. A. Giannella, G. Schiff, and M. M. 
Levine. 1999. Randomized, double-blind, placebo-controlled, multicentered trial of 
the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing 
cholera following challenge with Vibrio cholerae O1 El tor inaba three months after 
vaccination. Infection and immunity 67:6341-6345. 
164. Tacket, C. O., B. Forrest, R. Morona, S. R. Attridge, J. LaBrooy, B. D. Tall, M. 
Reymann, D. Rowley, and M. M. Levine. 1990. Safety, immunogenicity, and 
efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine 
derived from Salmonella typhi Ty21a. Infection and immunity 58:1620-1627. 
165. Tacket, C. O., G. Losonsky, J. P. Nataro, L. Comstock, J. Michalski, R. Edelman, 
J. B. Kaper, and M. M. Levine. 1995. Initial clinical studies of CVD 112 Vibrio 
cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. 
The Journal of infectious diseases 172:883-886. 
- 64 - 
166. Tacket, C. O., G. Losonsky, J. P. Nataro, S. J. Cryz, R. Edelman, A. Fasano, J. 
Michalski, J. B. Kaper, and M. M. Levine. 1993. Safety and immunogenicity of live 
oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of 
El Tor Ogawa Vibrio cholerae. The Journal of infectious diseases 168:1536-1540. 
167. Tacket, C. O., R. K. Taylor, G. Losonsky, Y. Lim, J. P. Nataro, J. B. Kaper, and 
M. M. Levine. 1998. Investigation of the roles of toxin-coregulated pili and mannose-
sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection. 
Infection and immunity 66:692-695. 
168. Taneja, N., A. Mishra, G. Sangar, G. Singh, and M. Sharma. 2009. Outbreaks 
caused by new variants of Vibrio cholerae O1 El Tor, India. Emerging infectious 
diseases 15:352-354. 
169. Taylor, D. N., K. P. Killeen, D. C. Hack, J. R. Kenner, T. S. Coster, D. T. Beattie, 
J. Ezzell, T. Hyman, A. Trofa, M. H. Sjogren, and et al. 1994. Development of a 
live, oral, attenuated vaccine against El Tor cholera. The Journal of infectious diseases 
170:1518-1523. 
170. Taylor, R. K., V. L. Miller, D. B. Furlong, and J. J. Mekalanos. 1987. Use of phoA 
gene fusions to identify a pilus colonization factor coordinately regulated with cholera 
toxin. Proceedings of the National Academy of Sciences of the United States of 
America 84:2833-2837. 
171. Ujiiye, A., M. Nakatomi, A. Utsunomiya, K. Mitsui, S. Sogame, M. Iwanaga, and 
K. Kobari. 1968. Experimental cholera in mice I. First report on the oral infection. 
Tropical Medicine 10:65-71. 
172. Waldor, M. K., R. Colwell, and J. J. Mekalanos. 1994. The Vibrio cholerae O139 
serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence 
determinants. Proceedings of the National Academy of Sciences of the United States 
of America 91:11388-11392. 
173. Waldor, M. K., and J. J. Mekalanos. 1996. Lysogenic conversion by a filamentous 
phage encoding cholera toxin. Science (New York, N.Y 272:1910-1914. 
174. van Loon, F. P., J. D. Clemens, J. Chakraborty, M. R. Rao, B. A. Kay, D. A. 
Sack, M. Yunus, M. Ali, A. M. Svennerholm, and J. Holmgren. 1996. Field trial of 
inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. 
Vaccine 14:162-166. 
175. Watnick, P. I., and R. Kolter. 1999. Steps in the development of a Vibrio cholerae 
El Tor biofilm. Molecular microbiology 34:586-595. 
176. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides. Extraction with 
phenol:water and further application of the procedure. In Methods in Carbohydrate 
Chemistry., vol. 5. Academic Press, New York. 
177. Vezzulli, L., C. A. Guzman, R. R. Colwell, and C. Pruzzo. 2008. Dual role 
colonization factors connecting Vibrio cholerae's lifestyles in human and aquatic 
environments open new perspectives for combating infectious diseases. Current 
opinion in biotechnology 19:254-259. 
178. Villavedra, M., H. Carol, M. Hjulstrom, J. Holmgren, and C. Czerkinsky. 1997. 
"PERFEXT": a direct method for quantitative assessment of cytokine production in 
vivo at the local level. Research in immunology 148:257-266. 
179. Vindurampulle, C. J., and S. R. Attridge. 2003. Impact of vector priming on the 
immunogenicity of recombinant Salmonella vaccines. Infection and immunity 71:287-
297. 
180. von Seidlein, L., X. Y. Wang, A. Macuamule, C. Mondlane, M. Puri, I. 
Hendriksen, J. L. Deen, C. L. Chaignat, J. D. Clemens, M. Ansaruzzaman, A. 
Barreto, F. F. Songane, and M. Lucas. 2008. Is HIV infection associated with an 
- 65 - 
increased risk for cholera? Findings from a case-control study in Mozambique. Trop 
Med Int Health 13:683-688. 
181. Voss, E., P. A. Manning, and S. R. Attridge. 1996. The toxin-coregulated pilus is a 
colonization factor and protective antigen of Vibrio cholerae El Tor. Microbial 
pathogenesis 20:141-153. 
182. Zuckerman, J. N., L. Rombo, and A. Fisch. 2007. The true burden and risk of 
cholera: implications for prevention and control. The Lancet infectious diseases 7:521-
530. 
 
 
